false 2025 Q2 0001659166 December 31 0.3333 P3Y 100 xbrli:shares iso4217:USD iso4217:USD xbrli:shares ftv:country iso4217:EUR iso4217:JPY xbrli:pure ftv:advance ftv:segment 0001659166 2025-01-01 2025-06-27 0001659166 ftv:EuroDenominatedSeniorNotes3Point7PercentDue2026Member 2025-01-01 2025-06-27 0001659166 ftv:EuroDenominatedSeniorNotes3Point7PercentDue2029Member 2025-01-01 2025-06-27 0001659166 2025-07-25 0001659166 2025-06-27 0001659166 2024-12-31 0001659166 us-gaap:ProductMember 2025-03-29 2025-06-27 0001659166 us-gaap:ProductMember 2024-03-30 2024-06-28 0001659166 us-gaap:ProductMember 2025-01-01 2025-06-27 0001659166 us-gaap:ProductMember 2024-01-01 2024-06-28 0001659166 us-gaap:ServiceMember 2025-03-29 2025-06-27 0001659166 us-gaap:ServiceMember 2024-03-30 2024-06-28 0001659166 us-gaap:ServiceMember 2025-01-01 2025-06-27 0001659166 us-gaap:ServiceMember 2024-01-01 2024-06-28 0001659166 2025-03-29 2025-06-27 0001659166 2024-03-30 2024-06-28 0001659166 2024-01-01 2024-06-28 0001659166 us-gaap:CommonStockMember 2024-12-31 0001659166 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001659166 us-gaap:TreasuryStockCommonMember 2024-12-31 0001659166 us-gaap:RetainedEarningsMember 2024-12-31 0001659166 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001659166 us-gaap:NoncontrollingInterestMember 2024-12-31 0001659166 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-28 0001659166 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-28 0001659166 us-gaap:CommonStockMember 2025-01-01 2025-03-28 0001659166 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-28 0001659166 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-03-28 0001659166 us-gaap:NoncontrollingInterestMember 2025-01-01 2025-03-28 0001659166 us-gaap:CommonStockMember 2025-03-28 0001659166 us-gaap:AdditionalPaidInCapitalMember 2025-03-28 0001659166 us-gaap:TreasuryStockCommonMember 2025-03-28 0001659166 us-gaap:RetainedEarningsMember 2025-03-28 0001659166 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-28 0001659166 us-gaap:NoncontrollingInterestMember 2025-03-28 0001659166 us-gaap:RetainedEarningsMember 2025-03-29 2025-06-27 0001659166 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-29 2025-06-27 0001659166 us-gaap:CommonStockMember 2025-03-29 2025-06-27 0001659166 us-gaap:AdditionalPaidInCapitalMember 2025-03-29 2025-06-27 0001659166 us-gaap:TreasuryStockCommonMember 2025-03-29 2025-06-27 0001659166 us-gaap:NoncontrollingInterestMember 2025-03-29 2025-06-27 0001659166 us-gaap:CommonStockMember 2025-06-27 0001659166 us-gaap:AdditionalPaidInCapitalMember 2025-06-27 0001659166 us-gaap:TreasuryStockCommonMember 2025-06-27 0001659166 us-gaap:RetainedEarningsMember 2025-06-27 0001659166 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-27 0001659166 us-gaap:NoncontrollingInterestMember 2025-06-27 0001659166 us-gaap:CommonStockMember 2023-12-31 0001659166 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001659166 us-gaap:TreasuryStockCommonMember 2023-12-31 0001659166 us-gaap:RetainedEarningsMember 2023-12-31 0001659166 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001659166 us-gaap:NoncontrollingInterestMember 2023-12-31 0001659166 us-gaap:RetainedEarningsMember 2024-03-30 2024-06-28 0001659166 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-30 2024-06-28 0001659166 us-gaap:CommonStockMember 2024-03-30 2024-06-28 0001659166 us-gaap:AdditionalPaidInCapitalMember 2024-03-30 2024-06-28 0001659166 us-gaap:CommonStockMember 2024-03-29 0001659166 us-gaap:AdditionalPaidInCapitalMember 2024-03-29 0001659166 us-gaap:TreasuryStockCommonMember 2024-03-29 0001659166 us-gaap:RetainedEarningsMember 2024-03-29 0001659166 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-29 0001659166 us-gaap:NoncontrollingInterestMember 2024-03-29 0001659166 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-29 0001659166 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-29 0001659166 us-gaap:CommonStockMember 2024-01-01 2024-03-29 0001659166 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-29 0001659166 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-03-29 0001659166 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-03-29 0001659166 us-gaap:CommonStockMember 2024-06-28 0001659166 us-gaap:AdditionalPaidInCapitalMember 2024-06-28 0001659166 us-gaap:TreasuryStockCommonMember 2024-06-28 0001659166 us-gaap:RetainedEarningsMember 2024-06-28 0001659166 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-28 0001659166 us-gaap:NoncontrollingInterestMember 2024-06-28 0001659166 2023-12-31 0001659166 2024-06-28 0001659166 ftv:PrecisionTechnologiesSegmentMember 2024-06-01 2024-06-28 0001659166 ftv:EuroDenominatedSeniorUnsecuredNotesDue2026Member 2025-06-27 0001659166 ftv:EuroDenominatedSeniorUnsecuredNotesDue2029Member 2025-06-27 0001659166 ftv:EuroTermLoanMember 2025-06-27 0001659166 ftv:YenTermLoanMember 2025-06-27 0001659166 us-gaap:AccumulatedTranslationAdjustmentMember 2025-03-28 0001659166 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2025-03-28 0001659166 us-gaap:AccumulatedTranslationAdjustmentMember 2025-03-29 2025-06-27 0001659166 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2025-03-29 2025-06-27 0001659166 us-gaap:AccumulatedTranslationAdjustmentMember 2025-06-27 0001659166 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2025-06-27 0001659166 us-gaap:AccumulatedTranslationAdjustmentMember 2024-03-29 0001659166 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-03-29 0001659166 us-gaap:AccumulatedTranslationAdjustmentMember 2024-03-30 2024-06-28 0001659166 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-03-30 2024-06-28 0001659166 us-gaap:AccumulatedTranslationAdjustmentMember 2024-06-28 0001659166 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-06-28 0001659166 us-gaap:AccumulatedTranslationAdjustmentMember 2024-12-31 0001659166 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-12-31 0001659166 us-gaap:AccumulatedTranslationAdjustmentMember 2025-01-01 2025-06-27 0001659166 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2025-01-01 2025-06-27 0001659166 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-06-27 0001659166 us-gaap:AccumulatedTranslationAdjustmentMember 2023-12-31 0001659166 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-12-31 0001659166 us-gaap:AccumulatedTranslationAdjustmentMember 2024-01-01 2024-06-28 0001659166 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-01-01 2024-06-28 0001659166 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-06-28 0001659166 srt:OfficeBuildingMember ftv:PrecisionTechnologiesSegmentMember 2024-03-14 0001659166 srt:OfficeBuildingMember ftv:PrecisionTechnologiesSegmentMember 2024-03-14 2024-03-14 0001659166 srt:OfficeBuildingMember ftv:PrecisionTechnologiesSegmentMember 2024-01-01 2024-06-28 0001659166 us-gaap:OtherRestructuringMember ftv:DiscreteRestructuringPlanMember 2025-03-29 2025-06-27 0001659166 us-gaap:OtherRestructuringMember ftv:DiscreteRestructuringPlanMember 2025-01-01 2025-06-27 0001659166 us-gaap:OtherRestructuringMember ftv:DiscreteRestructuringPlanMember 2025-06-27 0001659166 us-gaap:OtherRestructuringMember ftv:DiscreteRestructuringPlanMember 2024-12-31 0001659166 ftv:EAElektroAutomatikHoldingGmbHMember ftv:PrecisionTechnologiesSegmentMember 2024-01-03 2024-01-03 0001659166 ftv:EAElektroAutomatikHoldingGmbHMember ftv:PrecisionTechnologiesSegmentMember 2024-01-03 0001659166 ftv:EAElektroAutomatikHoldingGmbHMember ftv:PrecisionTechnologiesSegmentMember 2024-03-30 2024-06-28 0001659166 ftv:EAElektroAutomatikHoldingGmbHMember ftv:PrecisionTechnologiesSegmentMember 2024-01-01 2024-06-28 0001659166 ftv:RalliantMember 2025-03-29 2025-06-27 0001659166 ftv:RalliantMember 2025-01-01 2025-06-27 0001659166 ftv:RalliantMember ftv:RalliantMember 2025-06-16 2025-06-16 0001659166 ftv:IntelligentOperatingSolutionsMember 2024-12-31 0001659166 ftv:PrecisionTechnologiesSegmentMember 2024-12-31 0001659166 ftv:AdvancedHealthcareSolutionsMember 2024-12-31 0001659166 ftv:IntelligentOperatingSolutionsMember 2025-01-01 2025-06-27 0001659166 ftv:PrecisionTechnologiesSegmentMember 2025-01-01 2025-06-27 0001659166 ftv:AdvancedHealthcareSolutionsMember 2025-01-01 2025-06-27 0001659166 ftv:IntelligentOperatingSolutionsMember 2025-06-27 0001659166 ftv:PrecisionTechnologiesSegmentMember 2025-06-27 0001659166 ftv:AdvancedHealthcareSolutionsMember 2025-06-27 0001659166 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2025-06-27 0001659166 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2025-06-27 0001659166 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2025-06-27 0001659166 us-gaap:FairValueMeasurementsRecurringMember 2025-06-27 0001659166 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2024-12-31 0001659166 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2024-12-31 0001659166 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2024-12-31 0001659166 us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001659166 us-gaap:FairValueInputsLevel1Member 2025-06-27 0001659166 us-gaap:FairValueInputsLevel1Member 2024-12-31 0001659166 ftv:USDollarDenominatedCommercialPaperMember us-gaap:CommercialPaperMember 2025-06-27 0001659166 ftv:USDollarDenominatedCommercialPaperMember us-gaap:CommercialPaperMember 2024-12-31 0001659166 ftv:EuroDenominatedSeniorNotes3Point7PercentDue2026Member us-gaap:SeniorNotesMember 2025-06-27 0001659166 ftv:EuroDenominatedSeniorNotes3Point7PercentDue2026Member us-gaap:SeniorNotesMember 2024-12-31 0001659166 ftv:EuroDenominatedSeniorNotes3Point7PercentDue2029Member us-gaap:SeniorNotesMember 2025-06-27 0001659166 ftv:EuroDenominatedSeniorNotes3Point7PercentDue2029Member us-gaap:SeniorNotesMember 2024-12-31 0001659166 ftv:EuroTermLoanDueJune2025Member us-gaap:SecuredDebtMember 2025-06-27 0001659166 ftv:EuroTermLoanDueJune2025Member us-gaap:SecuredDebtMember 2024-12-31 0001659166 ftv:YenTermLoanDueJune2025Member us-gaap:SecuredDebtMember 2025-06-27 0001659166 ftv:YenTermLoanDueJune2025Member us-gaap:SecuredDebtMember 2024-12-31 0001659166 ftv:SeniorUnsecuredNotesdue2026Member us-gaap:SeniorNotesMember 2025-06-27 0001659166 ftv:SeniorUnsecuredNotesdue2026Member us-gaap:SeniorNotesMember 2024-12-31 0001659166 ftv:SeniorUnsecuredNotesdue2046Member us-gaap:SeniorNotesMember 2025-06-27 0001659166 ftv:SeniorUnsecuredNotesdue2046Member us-gaap:SeniorNotesMember 2024-12-31 0001659166 ftv:SubtotalMember 2025-06-27 0001659166 ftv:SubtotalMember 2024-12-31 0001659166 ftv:USDTermLoanDue2026Member ftv:RalliantMember us-gaap:SecuredDebtMember 2025-06-27 0001659166 ftv:USDTermLoanDue2026Member ftv:RalliantMember us-gaap:SecuredDebtMember 2024-12-31 0001659166 ftv:USDTermLoanDue2028Member ftv:RalliantMember us-gaap:SecuredDebtMember 2025-06-27 0001659166 ftv:USDTermLoanDue2028Member ftv:RalliantMember us-gaap:SecuredDebtMember 2024-12-31 0001659166 ftv:RalliantMember 2025-06-27 0001659166 ftv:RalliantMember 2024-12-31 0001659166 ftv:USDollarDenominatedCommercialPaperMember srt:MaximumMember us-gaap:CommercialPaperMember 2025-01-01 2025-06-27 0001659166 ftv:EuroDenominatedCommercialPaperMember srt:MaximumMember us-gaap:CommercialPaperMember 2025-01-01 2025-06-27 0001659166 ftv:USDollarDenominatedCommercialPaperMember us-gaap:CommercialPaperMember 2025-01-01 2025-06-27 0001659166 us-gaap:RevolvingCreditFacilityMember 2025-01-01 2025-06-27 0001659166 us-gaap:RevolvingCreditFacilityMember 2025-06-27 0001659166 us-gaap:LineOfCreditMember ftv:DelayedDrawThreeYearTermLoanMember ftv:RalliantMember 2025-05-15 2025-05-15 0001659166 us-gaap:LineOfCreditMember ftv:DelayedDrawThreeYearTermLoanMember ftv:RalliantMember 2025-05-15 0001659166 us-gaap:LineOfCreditMember ftv:DelayedDrawEighteenMonthTermLoanMember ftv:RalliantMember 2025-05-15 2025-05-15 0001659166 us-gaap:LineOfCreditMember ftv:DelayedDrawEighteenMonthTermLoanMember ftv:RalliantMember 2025-05-15 0001659166 us-gaap:RevolvingCreditFacilityMember ftv:RalliantMember 2025-05-15 2025-05-15 0001659166 us-gaap:RevolvingCreditFacilityMember ftv:RalliantMember 2025-05-15 0001659166 ftv:RalliantMember us-gaap:SecuredDebtMember 2025-05-15 0001659166 ftv:USDTermLoanDue2026AndUSDTermLoanDue2028Member ftv:RalliantMember 2025-06-27 0001659166 us-gaap:RevolvingCreditFacilityMember ftv:RalliantMember 2025-06-27 0001659166 ftv:RalliantMember 2025-01-01 2025-06-27 0001659166 ftv:EuroDenominatedSeniorNotes3Point7PercentDue2026Member ftv:RalliantMember us-gaap:SeniorNotesMember us-gaap:SubsequentEventMember 2025-07-15 2025-07-15 0001659166 ftv:EuroDenominatedSeniorNotes3Point7PercentDue2026Member us-gaap:DebtInstrumentRedemptionPeriodOneMember us-gaap:SeniorNotesMember us-gaap:SubsequentEventMember 2025-07-15 0001659166 ftv:EuroDenominatedSeniorNotes3Point7PercentDue2026Member us-gaap:SeniorNotesMember us-gaap:SubsequentEventMember 2025-07-15 0001659166 ftv:EuroDenominatedSeniorNotes3Point7PercentDue2026Member us-gaap:DebtInstrumentRedemptionPeriodTwoMember us-gaap:SeniorNotesMember us-gaap:SubsequentEventMember 2025-07-15 0001659166 ftv:EuroTermLoanDue2025Member ftv:RalliantMember us-gaap:SecuredDebtMember us-gaap:SubsequentEventMember 2025-07-24 2025-07-24 0001659166 ftv:YenTermLoanDue2025Member ftv:RalliantMember us-gaap:SecuredDebtMember us-gaap:SubsequentEventMember 2025-07-25 2025-07-25 0001659166 srt:MinimumMember 2025-06-27 0001659166 srt:MaximumMember 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:IntelligentOperatingSolutionsMember 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:PrecisionTechnologiesSegmentMember 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:AdvancedHealthcareSolutionsMember 2025-06-27 0001659166 ftv:PeriodOneMember 2025-06-28 2025-06-27 0001659166 ftv:PeriodTwoMember 2025-06-28 2025-06-27 0001659166 ftv:PeriodThreeMember 2025-06-28 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember us-gaap:ProductMember ftv:IntelligentOperatingSolutionsMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember us-gaap:ProductMember ftv:PrecisionTechnologiesSegmentMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember us-gaap:ProductMember ftv:AdvancedHealthcareSolutionsMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember ftv:IntelligentOperatingSolutionsMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember ftv:PrecisionTechnologiesSegmentMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember ftv:AdvancedHealthcareSolutionsMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:IntelligentOperatingSolutionsMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:PrecisionTechnologiesSegmentMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:AdvancedHealthcareSolutionsMember 2025-03-29 2025-06-27 0001659166 country:US 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember country:US ftv:IntelligentOperatingSolutionsMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember country:US ftv:PrecisionTechnologiesSegmentMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember country:US ftv:AdvancedHealthcareSolutionsMember 2025-03-29 2025-06-27 0001659166 country:CN 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember country:CN ftv:IntelligentOperatingSolutionsMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember country:CN ftv:PrecisionTechnologiesSegmentMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember country:CN ftv:AdvancedHealthcareSolutionsMember 2025-03-29 2025-06-27 0001659166 ftv:CountriesExcludingUnitedStatesandChinaMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:CountriesExcludingUnitedStatesandChinaMember ftv:IntelligentOperatingSolutionsMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:CountriesExcludingUnitedStatesandChinaMember ftv:PrecisionTechnologiesSegmentMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:CountriesExcludingUnitedStatesandChinaMember ftv:AdvancedHealthcareSolutionsMember 2025-03-29 2025-06-27 0001659166 us-gaap:HealthCareMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember us-gaap:HealthCareMember ftv:IntelligentOperatingSolutionsMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember us-gaap:HealthCareMember ftv:PrecisionTechnologiesSegmentMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember us-gaap:HealthCareMember ftv:AdvancedHealthcareSolutionsMember 2025-03-29 2025-06-27 0001659166 ftv:IndustrialManufacturingMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:IndustrialManufacturingMember ftv:IntelligentOperatingSolutionsMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:IndustrialManufacturingMember ftv:PrecisionTechnologiesSegmentMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:IndustrialManufacturingMember ftv:AdvancedHealthcareSolutionsMember 2025-03-29 2025-06-27 0001659166 us-gaap:GovernmentMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember us-gaap:GovernmentMember ftv:IntelligentOperatingSolutionsMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember us-gaap:GovernmentMember ftv:PrecisionTechnologiesSegmentMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember us-gaap:GovernmentMember ftv:AdvancedHealthcareSolutionsMember 2025-03-29 2025-06-27 0001659166 ftv:UtilitiesPowerMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:UtilitiesPowerMember ftv:IntelligentOperatingSolutionsMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:UtilitiesPowerMember ftv:PrecisionTechnologiesSegmentMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:UtilitiesPowerMember ftv:AdvancedHealthcareSolutionsMember 2025-03-29 2025-06-27 0001659166 ftv:CommunicationElectronicsAndSemiconductorMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:CommunicationElectronicsAndSemiconductorMember ftv:IntelligentOperatingSolutionsMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:CommunicationElectronicsAndSemiconductorMember ftv:PrecisionTechnologiesSegmentMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:CommunicationElectronicsAndSemiconductorMember ftv:AdvancedHealthcareSolutionsMember 2025-03-29 2025-06-27 0001659166 ftv:AerospaceAndDefenseMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:AerospaceAndDefenseMember ftv:IntelligentOperatingSolutionsMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:AerospaceAndDefenseMember ftv:PrecisionTechnologiesSegmentMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:AerospaceAndDefenseMember ftv:AdvancedHealthcareSolutionsMember 2025-03-29 2025-06-27 0001659166 ftv:RetailAndConsumerMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:RetailAndConsumerMember ftv:IntelligentOperatingSolutionsMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:RetailAndConsumerMember ftv:PrecisionTechnologiesSegmentMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:RetailAndConsumerMember ftv:AdvancedHealthcareSolutionsMember 2025-03-29 2025-06-27 0001659166 us-gaap:OilAndGasMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember us-gaap:OilAndGasMember ftv:IntelligentOperatingSolutionsMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember us-gaap:OilAndGasMember ftv:PrecisionTechnologiesSegmentMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember us-gaap:OilAndGasMember ftv:AdvancedHealthcareSolutionsMember 2025-03-29 2025-06-27 0001659166 ftv:OtherDirectEndMarketsMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:OtherDirectEndMarketsMember ftv:IntelligentOperatingSolutionsMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:OtherDirectEndMarketsMember ftv:PrecisionTechnologiesSegmentMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:OtherDirectEndMarketsMember ftv:AdvancedHealthcareSolutionsMember 2025-03-29 2025-06-27 0001659166 ftv:DirectEndMarketsMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:DirectEndMarketsMember ftv:IntelligentOperatingSolutionsMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:DirectEndMarketsMember ftv:PrecisionTechnologiesSegmentMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:DirectEndMarketsMember ftv:AdvancedHealthcareSolutionsMember 2025-03-29 2025-06-27 0001659166 ftv:OtherDistributorsMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:OtherDistributorsMember ftv:IntelligentOperatingSolutionsMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:OtherDistributorsMember ftv:PrecisionTechnologiesSegmentMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:OtherDistributorsMember ftv:AdvancedHealthcareSolutionsMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember us-gaap:ProductMember ftv:IntelligentOperatingSolutionsMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember us-gaap:ProductMember ftv:PrecisionTechnologiesSegmentMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember us-gaap:ProductMember ftv:AdvancedHealthcareSolutionsMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember ftv:IntelligentOperatingSolutionsMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember ftv:PrecisionTechnologiesSegmentMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember ftv:AdvancedHealthcareSolutionsMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:IntelligentOperatingSolutionsMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:PrecisionTechnologiesSegmentMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:AdvancedHealthcareSolutionsMember 2024-03-30 2024-06-28 0001659166 country:US 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember country:US ftv:IntelligentOperatingSolutionsMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember country:US ftv:PrecisionTechnologiesSegmentMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember country:US ftv:AdvancedHealthcareSolutionsMember 2024-03-30 2024-06-28 0001659166 country:CN 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember country:CN ftv:IntelligentOperatingSolutionsMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember country:CN ftv:PrecisionTechnologiesSegmentMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember country:CN ftv:AdvancedHealthcareSolutionsMember 2024-03-30 2024-06-28 0001659166 ftv:CountriesExcludingUnitedStatesandChinaMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:CountriesExcludingUnitedStatesandChinaMember ftv:IntelligentOperatingSolutionsMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:CountriesExcludingUnitedStatesandChinaMember ftv:PrecisionTechnologiesSegmentMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:CountriesExcludingUnitedStatesandChinaMember ftv:AdvancedHealthcareSolutionsMember 2024-03-30 2024-06-28 0001659166 us-gaap:HealthCareMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember us-gaap:HealthCareMember ftv:IntelligentOperatingSolutionsMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember us-gaap:HealthCareMember ftv:PrecisionTechnologiesSegmentMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember us-gaap:HealthCareMember ftv:AdvancedHealthcareSolutionsMember 2024-03-30 2024-06-28 0001659166 ftv:IndustrialManufacturingMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:IndustrialManufacturingMember ftv:IntelligentOperatingSolutionsMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:IndustrialManufacturingMember ftv:PrecisionTechnologiesSegmentMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:IndustrialManufacturingMember ftv:AdvancedHealthcareSolutionsMember 2024-03-30 2024-06-28 0001659166 us-gaap:GovernmentMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember us-gaap:GovernmentMember ftv:IntelligentOperatingSolutionsMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember us-gaap:GovernmentMember ftv:PrecisionTechnologiesSegmentMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember us-gaap:GovernmentMember ftv:AdvancedHealthcareSolutionsMember 2024-03-30 2024-06-28 0001659166 ftv:UtilitiesPowerMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:UtilitiesPowerMember ftv:IntelligentOperatingSolutionsMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:UtilitiesPowerMember ftv:PrecisionTechnologiesSegmentMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:UtilitiesPowerMember ftv:AdvancedHealthcareSolutionsMember 2024-03-30 2024-06-28 0001659166 ftv:CommunicationElectronicsAndSemiconductorMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:CommunicationElectronicsAndSemiconductorMember ftv:IntelligentOperatingSolutionsMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:CommunicationElectronicsAndSemiconductorMember ftv:PrecisionTechnologiesSegmentMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:CommunicationElectronicsAndSemiconductorMember ftv:AdvancedHealthcareSolutionsMember 2024-03-30 2024-06-28 0001659166 ftv:AerospaceAndDefenseMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:AerospaceAndDefenseMember ftv:IntelligentOperatingSolutionsMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:AerospaceAndDefenseMember ftv:PrecisionTechnologiesSegmentMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:AerospaceAndDefenseMember ftv:AdvancedHealthcareSolutionsMember 2024-03-30 2024-06-28 0001659166 ftv:RetailAndConsumerMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:RetailAndConsumerMember ftv:IntelligentOperatingSolutionsMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:RetailAndConsumerMember ftv:PrecisionTechnologiesSegmentMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:RetailAndConsumerMember ftv:AdvancedHealthcareSolutionsMember 2024-03-30 2024-06-28 0001659166 us-gaap:OilAndGasMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember us-gaap:OilAndGasMember ftv:IntelligentOperatingSolutionsMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember us-gaap:OilAndGasMember ftv:PrecisionTechnologiesSegmentMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember us-gaap:OilAndGasMember ftv:AdvancedHealthcareSolutionsMember 2024-03-30 2024-06-28 0001659166 ftv:OtherDirectEndMarketsMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:OtherDirectEndMarketsMember ftv:IntelligentOperatingSolutionsMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:OtherDirectEndMarketsMember ftv:PrecisionTechnologiesSegmentMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:OtherDirectEndMarketsMember ftv:AdvancedHealthcareSolutionsMember 2024-03-30 2024-06-28 0001659166 ftv:DirectEndMarketsMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:DirectEndMarketsMember ftv:IntelligentOperatingSolutionsMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:DirectEndMarketsMember ftv:PrecisionTechnologiesSegmentMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:DirectEndMarketsMember ftv:AdvancedHealthcareSolutionsMember 2024-03-30 2024-06-28 0001659166 ftv:OtherDistributorsMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:OtherDistributorsMember ftv:IntelligentOperatingSolutionsMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:OtherDistributorsMember ftv:PrecisionTechnologiesSegmentMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:OtherDistributorsMember ftv:AdvancedHealthcareSolutionsMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember us-gaap:ProductMember ftv:IntelligentOperatingSolutionsMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember us-gaap:ProductMember ftv:PrecisionTechnologiesSegmentMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember us-gaap:ProductMember ftv:AdvancedHealthcareSolutionsMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember ftv:IntelligentOperatingSolutionsMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember ftv:PrecisionTechnologiesSegmentMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember ftv:AdvancedHealthcareSolutionsMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:IntelligentOperatingSolutionsMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:PrecisionTechnologiesSegmentMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:AdvancedHealthcareSolutionsMember 2025-01-01 2025-06-27 0001659166 country:US 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember country:US ftv:IntelligentOperatingSolutionsMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember country:US ftv:PrecisionTechnologiesSegmentMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember country:US ftv:AdvancedHealthcareSolutionsMember 2025-01-01 2025-06-27 0001659166 country:CN 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember country:CN ftv:IntelligentOperatingSolutionsMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember country:CN ftv:PrecisionTechnologiesSegmentMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember country:CN ftv:AdvancedHealthcareSolutionsMember 2025-01-01 2025-06-27 0001659166 ftv:CountriesExcludingUnitedStatesandChinaMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:CountriesExcludingUnitedStatesandChinaMember ftv:IntelligentOperatingSolutionsMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:CountriesExcludingUnitedStatesandChinaMember ftv:PrecisionTechnologiesSegmentMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:CountriesExcludingUnitedStatesandChinaMember ftv:AdvancedHealthcareSolutionsMember 2025-01-01 2025-06-27 0001659166 us-gaap:HealthCareMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember us-gaap:HealthCareMember ftv:IntelligentOperatingSolutionsMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember us-gaap:HealthCareMember ftv:PrecisionTechnologiesSegmentMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember us-gaap:HealthCareMember ftv:AdvancedHealthcareSolutionsMember 2025-01-01 2025-06-27 0001659166 ftv:IndustrialManufacturingMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:IndustrialManufacturingMember ftv:IntelligentOperatingSolutionsMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:IndustrialManufacturingMember ftv:PrecisionTechnologiesSegmentMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:IndustrialManufacturingMember ftv:AdvancedHealthcareSolutionsMember 2025-01-01 2025-06-27 0001659166 us-gaap:GovernmentMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember us-gaap:GovernmentMember ftv:IntelligentOperatingSolutionsMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember us-gaap:GovernmentMember ftv:PrecisionTechnologiesSegmentMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember us-gaap:GovernmentMember ftv:AdvancedHealthcareSolutionsMember 2025-01-01 2025-06-27 0001659166 ftv:UtilitiesPowerMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:UtilitiesPowerMember ftv:IntelligentOperatingSolutionsMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:UtilitiesPowerMember ftv:PrecisionTechnologiesSegmentMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:UtilitiesPowerMember ftv:AdvancedHealthcareSolutionsMember 2025-01-01 2025-06-27 0001659166 ftv:CommunicationElectronicsAndSemiconductorMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:CommunicationElectronicsAndSemiconductorMember ftv:IntelligentOperatingSolutionsMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:CommunicationElectronicsAndSemiconductorMember ftv:PrecisionTechnologiesSegmentMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:CommunicationElectronicsAndSemiconductorMember ftv:AdvancedHealthcareSolutionsMember 2025-01-01 2025-06-27 0001659166 ftv:AerospaceAndDefenseMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:AerospaceAndDefenseMember ftv:IntelligentOperatingSolutionsMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:AerospaceAndDefenseMember ftv:PrecisionTechnologiesSegmentMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:AerospaceAndDefenseMember ftv:AdvancedHealthcareSolutionsMember 2025-01-01 2025-06-27 0001659166 ftv:RetailAndConsumerMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:RetailAndConsumerMember ftv:IntelligentOperatingSolutionsMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:RetailAndConsumerMember ftv:PrecisionTechnologiesSegmentMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:RetailAndConsumerMember ftv:AdvancedHealthcareSolutionsMember 2025-01-01 2025-06-27 0001659166 us-gaap:OilAndGasMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember us-gaap:OilAndGasMember ftv:IntelligentOperatingSolutionsMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember us-gaap:OilAndGasMember ftv:PrecisionTechnologiesSegmentMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember us-gaap:OilAndGasMember ftv:AdvancedHealthcareSolutionsMember 2025-01-01 2025-06-27 0001659166 ftv:OtherDirectEndMarketsMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:OtherDirectEndMarketsMember ftv:IntelligentOperatingSolutionsMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:OtherDirectEndMarketsMember ftv:PrecisionTechnologiesSegmentMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:OtherDirectEndMarketsMember ftv:AdvancedHealthcareSolutionsMember 2025-01-01 2025-06-27 0001659166 ftv:DirectEndMarketsMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:DirectEndMarketsMember ftv:IntelligentOperatingSolutionsMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:DirectEndMarketsMember ftv:PrecisionTechnologiesSegmentMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:DirectEndMarketsMember ftv:AdvancedHealthcareSolutionsMember 2025-01-01 2025-06-27 0001659166 ftv:OtherDistributorsMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:OtherDistributorsMember ftv:IntelligentOperatingSolutionsMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:OtherDistributorsMember ftv:PrecisionTechnologiesSegmentMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:OtherDistributorsMember ftv:AdvancedHealthcareSolutionsMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember us-gaap:ProductMember ftv:IntelligentOperatingSolutionsMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember us-gaap:ProductMember ftv:PrecisionTechnologiesSegmentMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember us-gaap:ProductMember ftv:AdvancedHealthcareSolutionsMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember ftv:IntelligentOperatingSolutionsMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember ftv:PrecisionTechnologiesSegmentMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember ftv:AdvancedHealthcareSolutionsMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:IntelligentOperatingSolutionsMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:PrecisionTechnologiesSegmentMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:AdvancedHealthcareSolutionsMember 2024-01-01 2024-06-28 0001659166 country:US 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember country:US ftv:IntelligentOperatingSolutionsMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember country:US ftv:PrecisionTechnologiesSegmentMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember country:US ftv:AdvancedHealthcareSolutionsMember 2024-01-01 2024-06-28 0001659166 country:CN 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember country:CN ftv:IntelligentOperatingSolutionsMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember country:CN ftv:PrecisionTechnologiesSegmentMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember country:CN ftv:AdvancedHealthcareSolutionsMember 2024-01-01 2024-06-28 0001659166 ftv:CountriesExcludingUnitedStatesandChinaMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:CountriesExcludingUnitedStatesandChinaMember ftv:IntelligentOperatingSolutionsMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:CountriesExcludingUnitedStatesandChinaMember ftv:PrecisionTechnologiesSegmentMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:CountriesExcludingUnitedStatesandChinaMember ftv:AdvancedHealthcareSolutionsMember 2024-01-01 2024-06-28 0001659166 us-gaap:HealthCareMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember us-gaap:HealthCareMember ftv:IntelligentOperatingSolutionsMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember us-gaap:HealthCareMember ftv:PrecisionTechnologiesSegmentMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember us-gaap:HealthCareMember ftv:AdvancedHealthcareSolutionsMember 2024-01-01 2024-06-28 0001659166 ftv:IndustrialManufacturingMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:IndustrialManufacturingMember ftv:IntelligentOperatingSolutionsMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:IndustrialManufacturingMember ftv:PrecisionTechnologiesSegmentMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:IndustrialManufacturingMember ftv:AdvancedHealthcareSolutionsMember 2024-01-01 2024-06-28 0001659166 us-gaap:GovernmentMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember us-gaap:GovernmentMember ftv:IntelligentOperatingSolutionsMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember us-gaap:GovernmentMember ftv:PrecisionTechnologiesSegmentMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember us-gaap:GovernmentMember ftv:AdvancedHealthcareSolutionsMember 2024-01-01 2024-06-28 0001659166 ftv:UtilitiesPowerMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:UtilitiesPowerMember ftv:IntelligentOperatingSolutionsMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:UtilitiesPowerMember ftv:PrecisionTechnologiesSegmentMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:UtilitiesPowerMember ftv:AdvancedHealthcareSolutionsMember 2024-01-01 2024-06-28 0001659166 ftv:CommunicationElectronicsAndSemiconductorMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:CommunicationElectronicsAndSemiconductorMember ftv:IntelligentOperatingSolutionsMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:CommunicationElectronicsAndSemiconductorMember ftv:PrecisionTechnologiesSegmentMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:CommunicationElectronicsAndSemiconductorMember ftv:AdvancedHealthcareSolutionsMember 2024-01-01 2024-06-28 0001659166 ftv:AerospaceAndDefenseMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:AerospaceAndDefenseMember ftv:IntelligentOperatingSolutionsMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:AerospaceAndDefenseMember ftv:PrecisionTechnologiesSegmentMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:AerospaceAndDefenseMember ftv:AdvancedHealthcareSolutionsMember 2024-01-01 2024-06-28 0001659166 ftv:RetailAndConsumerMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:RetailAndConsumerMember ftv:IntelligentOperatingSolutionsMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:RetailAndConsumerMember ftv:PrecisionTechnologiesSegmentMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:RetailAndConsumerMember ftv:AdvancedHealthcareSolutionsMember 2024-01-01 2024-06-28 0001659166 us-gaap:OilAndGasMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember us-gaap:OilAndGasMember ftv:IntelligentOperatingSolutionsMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember us-gaap:OilAndGasMember ftv:PrecisionTechnologiesSegmentMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember us-gaap:OilAndGasMember ftv:AdvancedHealthcareSolutionsMember 2024-01-01 2024-06-28 0001659166 ftv:OtherDirectEndMarketsMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:OtherDirectEndMarketsMember ftv:IntelligentOperatingSolutionsMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:OtherDirectEndMarketsMember ftv:PrecisionTechnologiesSegmentMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:OtherDirectEndMarketsMember ftv:AdvancedHealthcareSolutionsMember 2024-01-01 2024-06-28 0001659166 ftv:DirectEndMarketsMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:DirectEndMarketsMember ftv:IntelligentOperatingSolutionsMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:DirectEndMarketsMember ftv:PrecisionTechnologiesSegmentMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:DirectEndMarketsMember ftv:AdvancedHealthcareSolutionsMember 2024-01-01 2024-06-28 0001659166 ftv:OtherDistributorsMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:OtherDistributorsMember ftv:IntelligentOperatingSolutionsMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:OtherDistributorsMember ftv:PrecisionTechnologiesSegmentMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:OtherDistributorsMember ftv:AdvancedHealthcareSolutionsMember 2024-01-01 2024-06-28 0001659166 2025-06-28 2025-06-27 0001659166 ftv:RestrictedStockUnitsRSUsandPerformanceShareUnitsPSUsMember 2025-03-29 2025-06-27 0001659166 ftv:RestrictedStockUnitsRSUsandPerformanceShareUnitsPSUsMember 2024-03-30 2024-06-28 0001659166 ftv:RestrictedStockUnitsRSUsandPerformanceShareUnitsPSUsMember 2025-01-01 2025-06-27 0001659166 ftv:RestrictedStockUnitsRSUsandPerformanceShareUnitsPSUsMember 2024-01-01 2024-06-28 0001659166 us-gaap:EmployeeStockOptionMember 2025-03-29 2025-06-27 0001659166 us-gaap:EmployeeStockOptionMember 2024-03-30 2024-06-28 0001659166 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-06-27 0001659166 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-28 0001659166 ftv:RestrictedStockUnitsRSUsandPerformanceShareUnitsPSUsMember 2025-06-27 0001659166 us-gaap:EmployeeStockOptionMember 2025-06-27 0001659166 2022-02-17 0001659166 2024-01-23 0001659166 2025-05-27 0001659166 ftv:SpecialPurposeShareRepurchaseProgramMember 2025-05-27 0001659166 us-gaap:OperatingSegmentsMember ftv:PrecisionTechnologiesMember 2025-03-29 2025-06-27 0001659166 us-gaap:CorporateNonSegmentMember us-gaap:CorporateAndOtherMember 2025-03-29 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:PrecisionTechnologiesMember 2024-03-30 2024-06-28 0001659166 us-gaap:CorporateNonSegmentMember us-gaap:CorporateAndOtherMember 2024-03-30 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:PrecisionTechnologiesMember 2025-01-01 2025-06-27 0001659166 us-gaap:CorporateNonSegmentMember us-gaap:CorporateAndOtherMember 2025-01-01 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:PrecisionTechnologiesMember 2024-01-01 2024-06-28 0001659166 us-gaap:CorporateNonSegmentMember us-gaap:CorporateAndOtherMember 2024-01-01 2024-06-28 0001659166 us-gaap:OperatingSegmentsMember ftv:IntelligentOperatingSolutionsMember 2024-12-31 0001659166 us-gaap:OperatingSegmentsMember ftv:PrecisionTechnologiesMember 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember ftv:PrecisionTechnologiesMember 2024-12-31 0001659166 us-gaap:OperatingSegmentsMember ftv:AdvancedHealthcareSolutionsMember 2024-12-31 0001659166 us-gaap:OperatingSegmentsMember 2025-06-27 0001659166 us-gaap:OperatingSegmentsMember 2024-12-31 0001659166 us-gaap:CorporateNonSegmentMember 2025-06-27 0001659166 us-gaap:CorporateNonSegmentMember 2024-12-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________________________________
FORM 10-Q
________________________________________________

(Mark One) |
☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: June 27, 2025

Or
☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to

Commission file number 1-37654
________________________________________________
Fortive Corporation
(Exact name of registrant as specified in its charter)
________________________________________________

Delaware |  | 47-5654583
(State or other jurisdiction of incorporation or organization) |  | (I.R.S. employer identification number)

6920 Seaway Blvd |  |
Everett, | WA |  | 98203
(Address of principal executive offices) |  | (Zip code)

Registrant’s telephone number, including area code: (425) 446-5000
Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading symbol | Name of each exchange on which registered
Common stock, par value $0.01 per share | FTV | New York Stock Exchange
3.700% Notes due 2026 | FTV26A | New York Stock Exchange
3.700% Notes due 2029 | FTV29 | New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 (the “Exchange Act”) during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer | ☒ |  |  |  | Accelerated filer | ☐
Non-accelerated filer | ☐ |  |  |  | Smaller reporting company | ☐
|  |  |  |  | Emerging growth company | ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
The number of shares of common stock outstanding at July 25, 2025 was 338,336,345.

FORTIVE CORPORATION
INDEX
FORM 10-Q

PART I - | FINANCIAL INFORMATION | Page
Item 1. | Financial Statements |
| Consolidated Condensed Balance Sheets | 4
| Consolidated Condensed Statements of Earnings | 5
| Consolidated Condensed Statements of Comprehensive Income | 6
| Consolidated Condensed Statements of Changes in Equity | 7
| Consolidated Condensed Statements of Cash Flows | 8
| Notes to Consolidated Condensed Financial Statements | 9
Item 2. | Management's Discussion and Analysis of Financial Condition and Results of Operations | 26
Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 39
Item 4. | Controls and Procedures | 39
PART II - | OTHER INFORMATION |
Item 1A. | Risk Factors | 39
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 40
Item 5. | Other Information | 40
Item 6. | Exhibits | 40
| Signatures | 43

3

Table of Contents
PART I - FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
FORTIVE CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED BALANCE SHEETS
($ and shares in millions, except per share amounts)

| As of
| June 27, 2025 |  | December 31, 2024
| (unaudited) |  |
ASSETS |  |  |
Current assets: |  |  |
Cash and equivalents | $ | 1,832.7 |  |  | $ | 813.3 |
Accounts receivable less allowance for doubtful accounts of $27.2 and $30.7, respectively | 912.2 |  |  | 945.4 |
Inventories: |  |  |
Finished goods | 257.3 |  |  | 220.1 |
Work in process | 117.0 |  |  | 105.4 |
Raw materials | 236.1 |  |  | 219.3 |
Inventories | 610.4 |  |  | 544.8 |
Prepaid expenses and other current assets | 328.1 |  |  | 288.8 |
Total current assets | 3,683.4 |  |  | 2,592.3 |
Property, plant and equipment, net of accumulated depreciation of $857.8 and $828.6, respectively | 447.9 |  |  | 433.1 |
Other assets | 509.3 |  |  | 494.7 |
Goodwill | 10,403.7 |  |  | 10,156.0 |
Other intangible assets, net | 3,199.9 |  |  | 3,340.0 |
Total assets | $ | 18,244.2 |  |  | $ | 17,016.1 |
LIABILITIES AND EQUITY |  |  |
Current liabilities: |  |  |
Current portion of long-term debt | $ | 1,905.7 |  |  | $ | 376.2 |
Trade accounts payable | 700.5 |  |  | 677.4 |
Accrued expenses and other current liabilities | 1,139.4 |  |  | 1,184.8 |
Total current liabilities | 3,745.6 |  |  | 2,238.4 |
Other long-term liabilities | 1,202.9 |  |  | 1,251.0 |
Long-term debt | 2,906.5 |  |  | 3,331.1 |
Commitments and Contingencies (Note 9) |  |  |
Equity: |  |  |
Common stock: $0.01 par value, 2,000.0 shares authorized; 368.4 and 366.6 issued; 338.2 and 341.2 outstanding, respectively | 3.7 |  |  | 3.7 |
Additional paid-in capital | 4,106.0 |  |  | 4,035.0 |
Treasury shares, at cost | (1,952.2) |  |  | (1,612.3) |
Retained earnings | 8,511.9 |  |  | 8,227.6 |
Accumulated other comprehensive loss | (287.3) |  |  | (465.4) |
Total Fortive stockholders’ equity | 10,382.1 |  |  | 10,188.6 |
Noncontrolling interests | 7.1 |  |  | 7.0 |
Total stockholders’ equity | 10,389.2 |  |  | 10,195.6 |
Total liabilities and equity | $ | 18,244.2 |  |  | $ | 17,016.1 |

See the accompanying Notes to Consolidated Condensed Financial Statements.
4

Table of Contents
FORTIVE CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS
($ and shares in millions, except per share amounts)
(unaudited)

| Three Months Ended |  | Six Months Ended
| June 27, 2025 |  | June 28, 2024 |  | June 27, 2025 |  | June 28, 2024
Sales of products and software | $ | 1,277.4 |  |  | $ | 1,308.9 |  |  | $ | 2,525.8 |  |  | $ | 2,608.8 |
Sales of services | 241.4 |  |  | 243.5 |  |  | 467.2 |  |  | 468.1 |
Total sales | 1,518.8 |  |  | 1,552.4 |  |  | 2,993.0 |  |  | 3,076.9 |
Cost of product and software sales | (503.5) |  |  | (500.2) |  |  | (979.2) |  |  | (992.2) |
Cost of service sales | (119.6) |  |  | (123.9) |  |  | (237.2) |  |  | (252.2) |
Total cost of sales | (623.1) |  |  | (624.1) |  |  | (1,216.4) |  |  | (1,244.4) |
Gross profit | 895.7 |  |  | 928.3 |  |  | 1,776.6 |  |  | 1,832.5 |
Operating costs: |  |  |  |  |  |  |
Selling, general and administrative | (564.3) |  |  | (525.4) |  |  | (1,106.5) |  |  | (1,086.4) |
Research and development | (109.2) |  |  | (101.1) |  |  | (214.3) |  |  | (205.2) |
Gain on sale of property | — |  |  | — |  |  | — |  |  | 63.1 |
Operating profit | 222.2 |  |  | 301.8 |  |  | 455.8 |  |  | 604.0 |
Non-operating income (expense), net: |  |  |  |  |  |  |
Interest expense, net | (32.1) |  |  | (38.7) |  |  | (64.1) |  |  | (82.7) |
Loss from divestiture | — |  |  | (25.6) |  |  | — |  |  | (25.6) |
Other non-operating income (expense), net | 1.9 |  |  | (8.8) |  |  | 1.7 |  |  | (33.0) |
Earnings before income taxes | 192.0 |  |  | 228.7 |  |  | 393.4 |  |  | 462.7 |
Income taxes | (25.4) |  |  | (33.6) |  |  | (54.9) |  |  | (60.2) |
Net earnings | $ | 166.6 |  |  | $ | 195.1 |  |  | $ | 338.5 |  |  | $ | 402.5 |
Net earnings per share: |  |  |  |  |  |  |
Basic | $ | 0.49 |  |  | $ | 0.56 |  |  | $ | 0.99 |  |  | $ | 1.15 |
Diluted | $ | 0.49 |  |  | $ | 0.55 |  |  | $ | 0.99 |  |  | $ | 1.13 |
Average common stock and common equivalent shares outstanding: |  |  |  |  |  |  |
Basic | 339.6 |  |  | 351.3 |  |  | 340.3 |  |  | 351.5 |
Diluted | 341.7 |  |  | 354.8 |  |  | 343.2 |  |  | 355.4 |

See the accompanying Notes to Consolidated Condensed Financial Statements.
5

Table of Contents
FORTIVE CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
($ in millions)
(unaudited)

| Three Months Ended |  | Six Months Ended
| June 27, 2025 |  | June 28, 2024 |  | June 27, 2025 |  | June 28, 2024
Net earnings | $ | 166.6 |  |  | $ | 195.1 |  |  | $ | 338.5 |  |  | $ | 402.5 |
Other comprehensive income (loss), net of income taxes: |  |  |  |  |  |  |
Foreign currency translation adjustments | 108.0 |  |  | (21.1) |  |  | 178.1 |  |  | (97.6) |
Pension adjustments | — |  |  | — |  |  | — |  |  | 0.1 |
Total other comprehensive income (loss), net of income taxes | 108.0 |  |  | (21.1) |  |  | 178.1 |  |  | (97.5) |
Comprehensive income | $ | 274.6 |  |  | $ | 174.0 |  |  | $ | 516.6 |  |  | $ | 305.0 |

See the accompanying Notes to Consolidated Condensed Financial Statements.
6

Table of Contents
FORTIVE CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF CHANGES IN EQUITY
($ and shares in millions)
(unaudited)

| Common Stock |  | Additional Paid-In Capital |  | Treasury Shares |  | Retained Earnings |  | Accumulated Other Comprehensive Loss |  | Noncontrolling Interests
| Shares Outstanding |  | Amount
Balance, December 31, 2024 | 341.2 |  |  | $ | 3.7 |  |  | $ | 4,035.0 |  |  | $ | (1,612.3) |  |  | $ | 8,227.6 |  |  | $ | (465.4) |  |  | $ | 7.0 |
Net earnings for the period | — |  |  | — |  |  | — |  |  | — |  |  | 171.9 |  |  | — |  |  | — |
Dividends to common stockholders | — |  |  | — |  |  | — |  |  | — |  |  | (27.2) |  |  | — |  |  | — |
Other comprehensive income (loss) | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 70.1 |  |  | — |
Common stock-based award activity | 1.5 |  |  | — |  |  | 64.4 |  |  | — |  |  | — |  |  | — |  |  | — |
Common stock repurchases | (2.5) |  |  | — |  |  | — |  |  | (203.6) |  |  | — |  |  | — |  |  | — |
Shares withheld for taxes | (0.3) |  |  | — |  |  | (27.8) |  |  | — |  |  | — |  |  | — |  |  | — |
Change in noncontrolling interests | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (0.1) |
Balance, March 28, 2025 | 339.9 |  |  | $ | 3.7 |  |  | $ | 4,071.6 |  |  | $ | (1,815.9) |  |  | $ | 8,372.3 |  |  | $ | (395.3) |  |  | $ | 6.9 |
Net earnings for the period | — |  |  | — |  |  | — |  |  | — |  |  | 166.6 |  |  | — |  |  | — |
Dividends to common stockholders | — |  |  | — |  |  | — |  |  | — |  |  | (27.0) |  |  | — |  |  | — |
Other comprehensive income (loss) | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 108.0 |  |  | — |
Common stock-based award activity | 0.2 |  |  | — |  |  | 36.2 |  |  | — |  |  | — |  |  | — |  |  | — |
Common stock repurchases | (1.9) |  |  | — |  |  | — |  |  | (136.3) |  |  | — |  |  | — |  |  | — |
Shares withheld for taxes | — |  |  | — |  |  | (1.8) |  |  | — |  |  | — |  |  | — |  |  | — |
Change in noncontrolling interests | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 0.2 |
Balance, June 27, 2025 | 338.2 |  |  | $ | 3.7 |  |  | $ | 4,106.0 |  |  | $ | (1,952.2) |  |  | $ | 8,511.9 |  |  | $ | (287.3) |  |  | $ | 7.1 |

| Common Stock |  | Additional Paid-In Capital |  | Treasury Shares |  | Retained Earnings |  | Accumulated Other Comprehensive Loss |  | Noncontrolling Interests
| Shares Outstanding |  | Amount
Balance, December 31, 2023 | 350.7 |  |  | $ | 3.6 |  |  | $ | 3,851.3 |  |  | $ | (715.8) |  |  | $ | 7,505.9 |  |  | $ | (326.1) |  |  | $ | 6.4 |
Net earnings for the period | — |  |  | — |  |  | — |  |  | — |  |  | 207.4 |  |  | — |  |  | — |
Dividends to common stockholders | — |  |  | — |  |  | — |  |  | — |  |  | (28.1) |  |  | — |  |  | — |
Other comprehensive income (loss) | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (76.4) |  |  | — |
Common stock-based award activity | 1.5 |  |  | 0.1 |  |  | 73.2 |  |  | — |  |  | — |  |  | — |  |  | — |
Shares withheld for taxes | (0.2) |  |  | — |  |  | (18.4) |  |  | — |  |  | — |  |  | — |  |  | — |
Balance, March 29, 2024 | 352.0 |  |  | $ | 3.7 |  |  | $ | 3,906.1 |  |  | $ | (715.8) |  |  | $ | 7,685.2 |  |  | $ | (402.5) |  |  | $ | 6.4 |
Net earnings for the period | — |  |  | — |  |  | — |  |  | — |  |  | 195.1 |  |  | — |  |  | — |
Dividends to common shareholders | — |  |  | — |  |  | — |  |  | — |  |  | (28.0) |  |  | — |  |  | — |
Other comprehensive income (loss) | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (21.1) |  |  | — |
Common stock-based award activity | 0.3 |  |  | — |  |  | 35.0 |  |  | — |  |  | — |  |  | — |  |  | — |
Common stock repurchases | (2.0) |  |  | — |  |  | — |  |  | (154.6) |  |  | — |  |  | — |  |  | — |
Shares withheld for taxes | — |  |  | — |  |  | (3.8) |  |  | — |  |  | — |  |  | — |  |  | — |
Change in noncontrolling interests | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 0.1 |
Balance, June 28, 2024 | 350.3 |  |  | $ | 3.7 |  |  | $ | 3,937.3 |  |  | $ | (870.4) |  |  | $ | 7,852.3 |  |  | $ | (423.6) |  |  | $ | 6.5 |

See the accompanying Notes to Consolidated Condensed Financial Statements.
7

Table of Contents
FORTIVE CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
($ in millions)
(unaudited)

| Six Months Ended
| June 27, 2025 |  | June 28, 2024
Cash flows from operating activities: |  |  |
Net earnings | $ | 338.5 |  |  | $ | 402.5 |
Adjustments to reconcile net earnings to net cash provided by operating activities: |  |  |
Amortization | 225.0 |  |  | 227.1 |
Depreciation | 47.7 |  |  | 46.2 |
Stock-based compensation | 54.9 |  |  | 53.1 |
Gain on sale of property | — |  |  | (63.1) |
Loss from divestiture | — |  |  | 25.6 |
Change in certain assets and liabilities: |  |  |
Change in trade accounts receivable, net | 75.5 |  |  | 24.6 |
Change in inventories | (57.7) |  |  | (12.0) |
Change in trade accounts payable | 13.8 |  |  | 30.7 |
Change in prepaid expenses and other assets | (40.3) |  |  | (11.5) |
Change in accrued expenses and other liabilities | (104.5) |  |  | (157.6) |
Net cash provided by operating activities | 552.9 |  |  | 565.6 |
Cash flows from investing activities: |  |  |
Purchases of property, plant and equipment | (63.4) |  |  | (55.6) |
Proceeds from sale of property | 1.7 |  |  | 10.8 |
Cash paid for acquisitions, net of cash received | — |  |  | (1,721.8) |
Cash infusion into divestiture | — |  |  | (14.0) |
All other investing activities | 10.9 |  |  | (1.6) |
Net cash used in investing activities | (50.8) |  |  | (1,782.2) |
Cash flows from financing activities: |  |  |
Net proceeds from (repayments of) commercial paper borrowings | (253.2) |  |  | (571.5) |
Repurchase of common shares | (344.5) |  |  | (152.9) |
Payment of dividends | (54.2) |  |  | (56.1) |
Proceeds from borrowings (maturities greater than 90 days), net of issuance costs | 1,146.8 |  |  | 1,733.5 |
Repayment of borrowings (maturities greater than 90 days) | — |  |  | (1,000.0) |
All other financing activities | 14.4 |  |  | 31.9 |
Net cash provided by (used in) financing activities | 509.3 |  |  | (15.1) |
Effect of exchange rate changes on cash and equivalents | 8.0 |  |  | (13.0) |
Net change in cash and equivalents | 1,019.4 |  |  | (1,244.7) |
Beginning balance of cash and equivalents | 813.3 |  |  | 1,888.8 |
Ending balance of cash and equivalents | $ | 1,832.7 |  |  | $ | 644.1 |

See the accompanying Notes to Consolidated Condensed Financial Statements.
8

Table of Contents
FORTIVE CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
NOTE 1. BUSINESS OVERVIEW
Fortive Corporation (“Fortive,” “the Company,” “we,” “us,” or “our”) is a provider of essential technologies for connected workflow solutions across a range of attractive end-markets. Our strategic segments - Intelligent Operating Solutions (“IOS”), Precision Technologies (“PT”), and Advanced Healthcare Solutions (“AHS”) - include well-known brands with leading positions in their markets. Our businesses design, develop, manufacture, and service professional and engineered products, software, and services, building upon leading brand names, innovative technologies, and significant market positions. Our research and development, manufacturing, sales, distribution, service, and administrative facilities are located in more than 50 countries around the world.
We prepared the unaudited consolidated condensed financial statements included herein in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”) applicable for interim periods. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been omitted pursuant to such rules and regulations; however, we believe the disclosures are adequate to make the information presented not misleading. The unaudited consolidated condensed financial statements included herein should be read in conjunction with the audited annual consolidated financial statements as of and for the year ended December 31, 2024 and the footnotes (“Notes”) thereto included within our 2024 Annual Report on Form 10-K. Reclassification of certain prior year amounts in the changes in Accumulated Other Comprehensive Income (Loss) by component table below have been made to conform to current year presentation.
In our opinion, the accompanying financial statements contain all adjustments, which consist of only normal, recurring accruals necessary to fairly present our financial position, results of operations, comprehensive income, stockholders’ equity, and cash flows for the periods presented. The results of operations for the three and six months ended June 27, 2025, are not necessarily indicative of the results for the full year.
Precision Technologies Separation
On June 28, 2025 (the “Distribution Date”), the Company completed the separation (the “Separation” or the “PT Separation”) of its former Precision Technologies segment by distributing to Fortive shareholders on a pro rata basis all of the issued and outstanding common stock of Ralliant Corporation (“Ralliant”), the entity incorporated to hold the PT businesses. Refer to Note 2 for additional information.
Segment Realignment and Divestiture
In June 2024, we divested and transferred ownership of Invetech, excluding the Motion Solution Business, to its management team (the “Invetech Divestiture”). As a result, in the three and six-months period ended June 28, 2024, we recorded a net realized loss of $25.6 million, which is identified as “Loss from divestiture” in the Consolidated Condensed Statements of Earnings. The Invetech Divestiture did not represent a strategic shift with a major effect on the Company’s operations and financial results, and therefore the divested businesses are not reported as discontinued operations.
Accumulated Other Comprehensive Loss
Foreign currency translation adjustments are generally not adjusted for income taxes as they relate to indefinite investments in non-U.S. subsidiaries. As of June 27, 2025, our outstanding €500 million Euro-denominated senior unsecured notes due 2026, €700 million Euro-denominated senior unsecured notes due 2029, €275 million Euro-denominated term loan, and ¥14.4 billion Yen-denominated term loan were designated as net investment hedges of our investment in applicable foreign operations.
We recognized after-tax foreign currency transaction losses of $103.3 million and gains of $13.0 million during the three-month periods ended June 27, 2025 and June 28, 2024, respectively, and losses of $160.3 million and gains of $21.4 million during the six-month periods ended June 27, 2025 and June 28, 2024, respectively, on the debt that was deferred in the foreign currency translation component of Accumulated Other Comprehensive Income (Loss) (“AOCI”) as an offset to the foreign currency translation adjustments on our investments in foreign subsidiaries. Any amounts deferred in AOCI will remain until the hedged investment is sold or substantially liquidated. We recorded no ineffectiveness from our net investment hedges during the three and six-month periods ended June 27, 2025 and June 28, 2024. On the Distribution Date of the Separation, certain investments in foreign subsidiaries were transferred to Ralliant, resulting in a partial de-designation of net investment hedges on the outstanding foreign currency denominated debt instruments noted above. Foreign exchange gains and losses on any non-designated portion of the debt will be recognized in earnings beginning in Q3 2025.
9

Table of Contents
The changes in AOCI by component are summarized below ($ in millions):

| Foreign currency translation adjustments |  | Pension & post-retirement plan benefit adjustments (a) |  | Total
For the Three Months Ended June 27, 2025: |  |  |  |  |
Balance, March 28, 2025 | $ | (361.3) |  |  | $ | (34.0) |  |  | $ | (395.3) |
Other comprehensive income (loss) before reclassifications: |  |  |  |  |
Increase (decrease): | 120.7 |  |  | — |  |  | 120.7 |
Income tax impact | (12.7) |  |  | — |  |  | (12.7) |
Other comprehensive income (loss) before reclassifications, net of income taxes | 108.0 |  |  | — |  |  | 108.0 |
Amounts reclassified from AOCI into income: |  |  |  |  |
Increase (decrease) | — |  | (d) | — |  | (c, d) | — |
Income tax impact | — |  |  | — |  | (d) | — |
Amounts reclassified from AOCI into income, net of income taxes | — |  |  | — |  |  | — |
Net current period other comprehensive income (loss), net of income taxes | 108.0 |  |  | — |  |  | 108.0 |
Balance, June 27, 2025 | $ | (253.3) |  |  | $ | (34.0) |  |  | $ | (287.3) |
For the Three Months Ended June 28, 2024: |  |  |  |  |
Balance, March 29, 2024 | $ | (368.2) |  |  | $ | (34.3) |  |  | $ | (402.5) |
Other comprehensive income (loss) before reclassifications: |  |  |  |  |
Increase (decrease): | (33.1) |  |  | — |  |  | (33.1) |
Income tax impact | 5.0 |  |  | — |  |  | 5.0 |
Other comprehensive income (loss) before reclassifications, net of income taxes | (28.1) |  |  | — |  |  | (28.1) |
Amounts reclassified from AOCI into income: |  |  |  |  |
Increase (decrease) | 7.0 |  | (b) | 0.1 |  |  | 7.1 |
Income tax impact | — |  |  | (0.1) |  |  | (0.1) |
Amounts reclassified from AOCI into income, net of income taxes | 7.0 |  |  | — |  |  | 7.0 |
Net current period other comprehensive income (loss), net of income taxes | (21.1) |  |  | — |  |  | (21.1) |
Balance, June 28, 2024 | $ | (389.3) |  |  | $ | (34.3) |  |  | $ | (423.6) |
(a) Includes balances relating to defined benefit plans, supplemental executive retirement plans, and other postretirement employee benefit plans.
(b) This amount relates to the cumulative translation adjustment recognized in earnings upon the Invetech Divestiture. Refer to Note 1 for additional details.
(c) This component of AOCI is included in the computation of net periodic pension cost (refer to Note 10 in our 2024 Annual Report on Form 10-K for additional details).
(d) Amount was rounded to zero.

10

Table of Contents

| Foreign currency translation adjustments |  | Pension & post-retirement plan benefit adjustments (a) |  | Total
For the Six Months Ended June 27, 2025: |  |  |  |  |
Balance, December 31, 2024 | $ | (431.4) |  |  | $ | (34.0) |  |  | $ | (465.4) |
Other comprehensive income (loss) before reclassifications: |  |  |  |  |
Increase (decrease): | 198.7 |  |  | — |  |  | 198.7 |
Income tax impact | (20.6) |  |  | — |  |  | (20.6) |
Other comprehensive income (loss) before reclassifications, net of income taxes | 178.1 |  |  | — |  |  | 178.1 |
Amounts reclassified from AOCI into income: |  |  |  |  |
Increase (decrease) | — |  | (d) | — |  | (c, d) | — |
Income tax impact | — |  |  | — |  | (d) | — |
Amounts reclassified from AOCI into income, net of income taxes | — |  |  | — |  |  | — |
Net current period other comprehensive income (loss) | 178.1 |  |  | — |  |  | 178.1 |
Balance, June 27, 2025 | $ | (253.3) |  |  | $ | (34.0) |  |  | $ | (287.3) |
For the Six Months Ended June 28, 2024: |  |  |  |  |
Balance, December 31, 2023 | $ | (291.7) |  |  | $ | (34.4) |  |  | $ | (326.1) |
Other comprehensive income (loss) before reclassifications: |  |  |  |  |
Increase (decrease): | (113.2) |  |  | — |  |  | (113.2) |
Income tax impact | 8.6 |  |  | — |  |  | 8.6 |
Other comprehensive income (loss) before reclassifications, net of income taxes | (104.6) |  |  | — |  |  | (104.6) |
Amounts reclassified from AOCI into income: |  |  |  |  |
Increase (decrease) | 7.0 |  | (b) | 0.2 |  | (c) | 7.2 |
Income tax impact | — |  |  | (0.1) |  |  | (0.1) |
Amounts reclassified from AOCI into income, net of income taxes | 7.0 |  |  | 0.1 |  |  | 7.1 |
Net current period other comprehensive income (loss) | (97.6) |  |  | 0.1 |  |  | (97.5) |
Balance, June 28, 2024 | $ | (389.3) |  |  | $ | (34.3) |  |  | $ | (423.6) |
(a) Includes balances relating to defined benefit plans, supplemental executive retirement plans, and other postretirement employee benefit plans.
(b) This amount relates to the cumulative translation adjustment recognized in earnings upon the Invetech Divestiture. Refer to Note 1 for additional details.
(c) This component of AOCI is included in the computation of net periodic pension cost (refer to Note 10 in our 2024 Annual Report on Form 10-K for additional details).
(d) Amount was rounded to zero.

Allowance for Doubtful Accounts
All trade accounts and unbilled receivables are recorded in the Consolidated Condensed Balance Sheets adjusted for any write-offs and net of allowances for credit losses. The allowances for credit losses represent management’s best estimate of the credit losses expected from our unbilled and trade accounts receivable portfolios over the life of the underlying assets. Additions to the allowances are charged to current period earnings, amounts determined to be uncollectible are charged directly against the allowances, while amounts recovered on previously written-off accounts increase the allowances. During the three and six-month periods ending June 27, 2025 and June 28, 2024, the activity was immaterial.
Property Sale
On March 14, 2024, we sold land and certain office buildings in our PT segment for $90 million, for which we received $20 million in cash proceeds and a $70 million promissory note secured by a letter of credit, with principal received in August and November 2024. The promissory note was recorded within Prepaid expenses and other current assets. During the six-month period ended June 28, 2024, we recorded a gain on sale of property of $63.1 million in the Consolidated Condensed Statements of Earnings.
11

Table of Contents
Concurrently, using a portion of the proceeds from the property sale, we pledged a charitable contribution of $20 million to the Fortive Foundation (the “Foundation”), which had no donor imposed conditions or restrictions. The Foundation, a not-for-profit entity established to expand our philanthropic efforts, is a related party due to certain Fortive executives serving as members of the entity’s board of directors. The charitable contribution was recorded within the “Other non-operating expense, net” line in the Consolidated Condensed Statements of Earnings.
Restructuring
In the fourth quarter of 2024, we initiated a discrete restructuring plan that is expected to be completed by December 31, 2025. The nature of the plan initiated in 2024 was related to the Separation and consisted primarily of targeted workforce reductions to realign cost structures. During the three and six-month periods ended June 27, 2025, we incurred charges of $8 million and $12 million, respectively. Accrued restructuring costs were $8 million as of June 27, 2025 and were $13 million as of December 31, 2024, and are recorded within Accrued expenses and other current liabilities in the Consolidated Condensed Balance Sheets.
Recently Issued Accounting Standard
In December 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-09, Income Taxes (Topic 740)—Improvements to Income Tax Disclosures, which amends certain disclosure requirements related to income taxes on an annual basis. This standard is effective for fiscal year ending December 31, 2025. This standard should be applied on a prospective basis, with retrospective application permitted. The adoption of the standard will not impact our consolidated financial statements; however, we are currently evaluating the impact of the new disclosure requirements on the notes to the financial statements. We will update the applicable annual disclosures to align with the new standard.
In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40) — Disaggregation of Income Statement Expenses, which amends the disclosure requirements related to certain costs and expenses on an interim and annual basis. This standard is effective for fiscal year ending December 31, 2027, and interim periods within fiscal year ending December 31, 2028. This standard should be applied either on a prospective basis or retrospective basis. The adoption of the standard will not impact our combined financial statements; however, we are currently evaluating the impact of the new disclosure requirements on the notes to the financial statements. Upon adoption, we will update the applicable interim and annual disclosures to align with the new standard.
NOTE 2. ACQUISITIONS AND DIVESTITURES
We continually evaluate potential mergers and acquisitions that align with our business portfolio strategy. We have completed a number of acquisitions that have been accounted for as purchases of businesses and resulted in the recognition of goodwill in our financial statements. This goodwill arises when the purchase price for an acquired business exceeds its identifiable assets, net of liabilities. The purchase price for acquired businesses reflect a number of factors, including the future earnings and cash flow potential of the business, the strategic fit and resulting synergies from the complementary portfolio of the acquired business to our existing operations, industry expertise, and market access.
On January 3, 2024, we acquired EA Elektro-Automatik Holding GmbH (“EA”), a leading supplier of high-power electronic test solutions for energy storage, mobility, hydrogen, and renewable energy applications, with EA operating within the PT segment following the acquisition. The total consideration paid was approximately $1.72 billion, net of acquired cash. We funded this transaction with financing activities and available cash. We recorded approximately $1.18 billion of goodwill within our PT segment related to the EA acquisition, which is not tax deductible.
For the three and six-month periods ended June 28, 2024, we incurred approximately $0.2 million and $27.4 million of pretax transaction-related costs related to the EA acquisition, which were primarily for banking fees, legal fees, and amounts paid to other third-party advisers. These costs were recorded within Selling, general, and administrative expenses in the Consolidated Condensed Statement of Earnings.
Subsequent to the end of the second quarter, on June 28, 2025, the Company completed the PT Separation by distributing to its stockholders one share of Ralliant common stock for every three shares of the Company’s common stock outstanding held on June 16, 2025, the record date for the distribution. Fortive stockholders received cash in lieu of any fractional shares of Ralliant common stock that they would have received after application of this ratio. Beginning with the third quarter of 2025, the Company will classify Ralliant as a discontinued operation in its financial statements, as a result of the Separation. Refer to Note 11 for PT’s operating results.
12

Table of Contents
In connection with the Separation, the Company incurred $41 million and $64 million in Separation-related costs during the three and six months ended June 27, 2025, respectively. These costs were primarily related to professional fees associated with finance, tax, legal, banking and information technology services as well as redundant general and administrative costs, and were recorded within Selling, general and administrative expenses in the Consolidated Condensed Statements of Earnings.
Fortive and Ralliant entered into various agreements to effect the Separation and provide a framework for their relationship after the Separation, including a separation and distribution agreement, a transition services agreement, an employee matters agreement, a tax matters agreement, an intellectual property matters agreement, a Fortive Business System (“FBS”) license agreement and a Fort solutions license agreement. These agreements provide for the allocation between Fortive and Ralliant of assets, employees, liabilities and obligations (including investments, property, employee benefits and tax-related assets and liabilities) attributable to periods prior to, at and after the Separation and govern certain relationships between Fortive and Ralliant after the Separation.
NOTE 3. GOODWILL
The following is a roll forward of our carrying value of goodwill by segment ($ in millions):

| Intelligent Operating Solutions |  | Precision Technologies |  | Advanced Healthcare Solutions |  | Total Goodwill
Balance, December 31, 2024 | $ | 4,121.7 |  |  | $ | 2,940.0 |  |  | $ | 3,094.3 |  |  | $ | 10,156.0 |
Foreign currency translation and other | 47.2 |  |  | 179.1 |  |  | 21.4 |  |  | 247.7 |
Balance, June 27, 2025 | $ | 4,168.9 |  |  | $ | 3,119.1 |  |  | $ | 3,115.7 |  |  | $ | 10,403.7 |

NOTE 4. FAIR VALUE MEASUREMENTS
Accounting standards define fair value based on an exit price model, establish a framework for measuring fair value for assets and liabilities required to be carried at fair value, and provide for certain disclosures related to the valuation methods used within the valuation hierarchy as established within the accounting standards. This hierarchy prioritizes the inputs into three broad levels as follows:
•Level 1 inputs are quoted prices (unadjusted) for identical assets or liabilities in active markets.
•Level 2 inputs are quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in markets that are not active, or other observable characteristics for the asset or liability, including interest rates, yield curves and credit risks, or inputs that are derived principally from, or corroborated by, observable market data through correlation.
•Level 3 inputs are unobservable inputs based on our assumptions. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement in its entirety.
Below is a summary of financial liabilities that are measured at fair value on a recurring basis ($ in millions):

| Quoted Prices in Active Market (Level 1) |  | Significant Other Observable Inputs (Level 2) |  | Significant Unobservable Inputs (Level 3) |  | Total
June 27, 2025 |  |  |  |  |  |  |
Deferred compensation liabilities | $ | — |  |  | $ | 37.7 |  |  | $ | — |  |  | $ | 37.7 |
December 31, 2024 |  |  |  |  |  |  |
Deferred compensation liabilities | — |  |  | 46.7 |  |  | — |  |  | 46.7 |

Certain management employees participate in our nonqualified deferred compensation programs that permit such employees to defer a portion of their compensation, on a pretax basis, until after their termination of employment. All amounts deferred under such plans are unfunded, unsecured obligations and are recorded within Other long-term liabilities in the accompanying Consolidated Condensed Balance Sheets. Participants may choose among alternative earning rates for the amounts they defer, which are primarily based on investment options within our defined contribution plans for the benefit of U.S. employees (except that the earnings rates for amounts contributed unilaterally by the Company are entirely based on changes in the value of Fortive common stock). Changes in the deferred compensation liability under these programs are recognized based on changes in the fair value of the participants’ accounts and are recorded within Selling, general and administrative expenses in the Consolidated Condensed Statements of Earnings.
13

Table of Contents
Non-recurring Fair Value Measurements
Certain non-financial assets, primarily property, plant, and equipment, goodwill, and intangible assets, are not required to be measured at fair value on a recurring basis and are reported at their carrying value. However, these assets are required to be assessed for impairment whenever events or circumstances indicate that their carrying value may not be fully recoverable, and at least annually for goodwill and indefinite-lived intangible assets. We evaluated events or circumstances that may indicate the carrying value of our non-financial assets may not be fully recoverable during the three and six-month period ended June 27, 2025, and recorded no impairments.
Fair Value of Financial Instruments
The carrying amount and fair value of financial instruments are as follows ($ in millions):

| June 27, 2025 |  | December 31, 2024
| Carrying Amount |  | Fair Value |  | Carrying Amount |  | Fair Value
Current portion of long-term debt | $ | 1,905.7 |  |  | $ | 1,900.7 |  |  | $ | 376.2 |  |  | $ | 376.3 |
Long-term debt, net of current maturities | 2,906.5 |  |  | 2,837.2 |  |  | 3,331.1 |  |  | 3,243.8 |

As of June 27, 2025 and December 31, 2024, the current portion of long-term debt and long-term debt, net of current maturities were categorized as Level 1.
The fair value of the long-term borrowings were based on quoted market prices. The difference between the fair value and the carrying amounts of long-term borrowings may be attributable to changes in market interest rates and/or our credit ratings subsequent to the borrowing. The fair value of cash and equivalents, trade accounts receivable, net, trade accounts payable, and commercial paper approximates their carrying amount due to the short-term maturities of these instruments.
NOTE 5. FINANCING
The components of our debt were as follows ($ in millions):

| June 27, 2025 |  | December 31, 2024 |
U.S. dollar-denominated commercial paper | $ | 395.0 |  |  | $ | 650.0 |  |
3.7% Euro-denominated senior unsecured notes due 2026 | 585.9 |  |  | 517.7 |  |
3.7% Euro-denominated senior unsecured notes due 2029 | 820.3 |  |  | 724.8 |  |
Euro Term Loan due 2025 | 322.2 |  |  | 284.7 |  |
Yen Term Loan due 2025 | 99.6 |  |  | 91.6 |  |
3.15% senior unsecured notes due 2026 | 900.0 |  |  | 900.0 |  |
4.30% senior unsecured notes due 2046 | 550.0 |  |  | 550.0 |  |
Subtotal | 3,673.0 |  |  | 3,718.8 |  |
Ralliant debt: |  |  |  |
USD Term Loan due 2026 | 530.8 |  |  | — |  |
USD Term Loan due 2028 | 619.2 |  |  | — |  |
Total Ralliant debt | 1,150.0 |  |  | — |  |
Long-term debt, principal amounts | 4,823.0 |  |  | 3,718.8 |  |
Less: aggregate unamortized debt discounts, premiums, and issuance costs | 10.8 |  |  | 11.5 |  |
Long-term debt, carrying value | 4,812.2 |  |  | 3,707.3 |  |
Less: current portion of long-term debt, carrying value | 1,905.7 |  |  | 376.2 |  |
Long-term debt, net of current maturities | $ | 2,906.5 |  |  | $ | 3,331.1 |  |

Refer to Note 9 of our 2024 Annual Report on Form 10-K for further details of our debt financing.
Commercial Paper Programs
We generally satisfy any short-term liquidity needs that are not met through operating cash flows and available cash primarily through issuances of commercial paper under our U.S. dollar and Euro-denominated commercial paper programs (“Commercial Paper Programs”). Under these programs, we may issue unsecured promissory notes with maturities not exceeding 397 and 183
14

Table of Contents
days, respectively. Proceeds from borrowings under the commercial paper programs are typically available for general corporate purposes, including acquisitions.
Interest expense on commercial paper is paid at maturity and is generally based on our credit ratings at the time of issuance and prevailing short-term interest rates.
The details of our outstanding Commercial Paper Programs as of June 27, 2025 were as follows ($ in millions):

| Carrying value (a) |  | Annual effective rate |  | Weighted average maturity (in days)
U.S. dollar-denominated commercial paper | $ | 394.2 |  |  | 4.63 | % |  | 30
(a) Net of unamortized debt discount.

Credit support for the Commercial Paper Programs is provided by a five-year $2.0 billion senior unsecured revolving credit facility that expires on October 18, 2027 (the “Revolving Credit Facility”) which, to the extent not otherwise providing credit support for our commercial paper programs, can also be used for working capital and other general corporate purposes. As of June 27, 2025, no borrowings were outstanding under the Revolving Credit Facility.
We classified our borrowings outstanding under the Commercial Paper Programs as of June 27, 2025 as Long-term debt in the accompanying Consolidated Condensed Balance Sheets as we had the intent and ability, as supported by availability under the Revolving Credit Facility, to refinance these borrowings for at least one year from the balance sheet date.
Indebtedness Related to the Ralliant Separation
On May 15, 2025, Ralliant entered into a credit agreement with a syndicate of banks, consisting of a three-year, $700 million senior unsecured delayed draw term loan facility (the “Three-Year Term Loans”), an eighteen-month, $600 million senior unsecured delayed draw term loan facility (the “Eighteen-Month Term Loans” and together with the Three-Year Term Loans, the “Term Loans”), and a five-year $750 million unsecured revolving credit facility (the “Ralliant Credit Facility”).
Ralliant may draw on the funds under the Term Loans, in up to two advances, which may be made on or prior to December 31, 2025. On June 27, 2025, in preparation for the Separation, Ralliant borrowed $1.15 billion in aggregate principal amount consisting of a USD Term Loan due 2026 and a USD Term Loan due 2028 (the “Ralliant Debt”). As of June 27, 2025, Ralliant was a wholly-owned, consolidated subsidiary of the Company, and as a result, the Company’s Consolidated Balance Sheet includes the Ralliant Debt.
No amounts were outstanding under the Ralliant Credit Facility at any time prior to the Separation. As of June 27, 2025, Ralliant was in compliance with all covenants under the Ralliant Debt and the Ralliant Credit Facility.
The proceeds from the Ralliant Debt were used to fund the $1.15 billion cash dividend Ralliant made to Fortive prior to the Distribution Date (the “Ralliant Dividend”).
Use of Ralliant Dividend
On June 4, 2025 and June 17, 2025, respectively, we extended the maturity date of the Yen Term Loan due on June 17, 2025 and the Euro Term Loan due on June 23, 2025 to December 31, 2025.
On July 15, 2025, Fortive used approximately $302 million of the Ralliant Dividend to redeem €252 million of the outstanding principal of the 3.7% Euro-denominated senior unsecured notes due 2026, and the accrued interest thereon, with €248 million remaining outstanding following such redemption. On July 24, 2025 and July 25, 2025, respectively, Fortive used $324 million and $98 million of the Ralliant Dividend to repay the outstanding principle of the Euro Term Loan and Yen Term Loan, and accrued interest thereon. Fortive also intends to apply the Ralliant Dividend to repurchase certain of its outstanding common stock pursuant to the special purpose share repurchase program authorized on May 27, 2025.
NOTE 6. SALES
We derive revenue primarily from the sales of products, including software, and services. Revenue is recognized when control of promised products or services is transferred to customers in an amount that reflects the consideration we expect to be entitled to in exchange for those products, software, or services.
Product sales include revenue from the sale of products and equipment, which includes our software and software as a service (“SaaS”) product offerings and equipment rentals. Service sales include revenues from extended warranties, post-contract
15

Table of Contents
customer support (“PCS”), maintenance contracts or services, contract labor to perform ongoing service at a customer location, services related to previously sold products, and software implementation services.
Contract Assets — In certain circumstances, we record contract assets which include unbilled amounts typically resulting from sales under contracts when revenue recognized exceeds the amount billed to the customer, and right to payment is not only subject to the passage of time. Contract assets were $141 million as of June 27, 2025 and $118 million as of December 31, 2024. Contract assets are recorded within Prepaid expenses and other current assets in our Consolidated Condensed Balance Sheets.
Contract Costs — We incur and capitalize incremental costs to obtain certain contracts, typically sales-related commissions where the amortization period is greater than one year and costs associated with assets used by our customers in certain service arrangements. As of June 27, 2025 and December 31, 2024, we had $69 million and $59 million, respectively, in net revenue-related contract costs primarily related to certain software contracts. Revenue-related contract costs are recorded within Other assets in our Consolidated Condensed Balance Sheets. These assets have estimated useful lives between three and five years.
Contract Liabilities — Our contract liabilities consist of deferred revenue generally related to subscription-based software contracts, PCS and extended warranty sales, where we generally receive up-front payment and recognize revenue over the service or support term. We classify deferred revenue as current or noncurrent based on the timing of when we expect to recognize revenue. The current portion of deferred revenue is recorded within Accrued expenses and other current liabilities and the noncurrent portion of deferred revenue is recorded within Other long-term liabilities in our Consolidated Condensed Balance Sheets.
Our contract liabilities consisted of the following ($ in millions):

| June 27, 2025 |  | December 31, 2024
Deferred revenue - current | $ | 565.9 |  |  | $ | 553.2 |
Deferred revenue - noncurrent | 62.4 |  |  | 58.9 |
Total contract liabilities | $ | 628.3 |  |  | $ | 612.1 |

During the three and six-month period ended June 27, 2025, we recognized revenue related to our contract liabilities at December 31, 2024 of $128 million and $317 million, respectively. The change in our contract liabilities from December 31, 2024 to June 27, 2025 was primarily due to the timing of billings and revenue recognized for subscription-based software contracts, PCS and extended warranty services.
Remaining Performance Obligations — Our remaining performance obligations represent the transaction price of firm, non-cancelable orders and the average contract value for software contracts, for which work has not been performed. We have excluded performance obligations with an original expected duration of one year or less from the amounts below.
The aggregate remaining performance obligations attributable to each of our segments is as follows ($ in millions):

| June 27, 2025
Intelligent Operating Solutions | $ | 647.0 |
Precision Technologies | 61.9 |
Advanced Healthcare Solutions | 104.1 |
Total remaining performance obligations | $ | 813.0 |

The majority of remaining performance obligations are related to service and support contracts, which we expect to fulfill approximately 75 percent within the next two years, approximately 90 percent within the next three years, and substantially all within four years.
16

Table of Contents
Disaggregation of Revenue
We disaggregate revenue from contracts with customers by sales of products and software and services, geographic location, and end market for each of our segments, as we believe it best depicts how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors.
Disaggregation of revenue for the three-month period ended June 27, 2025 is presented as follows ($ in millions):

| Total |  | Intelligent Operating Solutions |  | Precision Technologies |  | Advanced Healthcare Solutions
Sales: |  |  |  |  |  |  |
Sales of products and software | $ | 1,277.4 |  |  | $ | 562.5 |  |  | $ | 465.0 |  |  | $ | 249.9 |
Sales of services | 241.4 |  |  | 113.2 |  |  | 58.6 |  |  | 69.6 |
Total | $ | 1,518.8 |  |  | $ | 675.7 |  |  | $ | 523.6 |  |  | $ | 319.5 |
Geographic: |  |  |  |  |  |  |
United States | $ | 825.2 |  |  | $ | 379.9 |  |  | $ | 264.5 |  |  | $ | 180.8 |
China | 159.7 |  |  | 49.5 |  |  | 85.6 |  |  | 24.6 |
All other | 533.9 |  |  | 246.3 |  |  | 173.5 |  |  | 114.1 |
Total | $ | 1,518.8 |  |  | $ | 675.7 |  |  | $ | 523.6 |  |  | $ | 319.5 |
End markets:(a) |  |  |  |  |  |  |
Direct sales: |  |  |  |  |  |  |
Healthcare | $ | 360.0 |  |  | $ | 10.6 |  |  | $ | 46.9 |  |  | $ | 302.5 |
Industrial & Manufacturing | 329.5 |  |  | 231.3 |  |  | 93.7 |  |  | 4.5 |
Government | 133.0 |  |  | 79.6 |  |  | 44.3 |  |  | 9.1 |
Utilities & Power | 114.9 |  |  | 48.4 |  |  | 66.5 |  |  | — |
Communications, Electronics & Semiconductor | 84.3 |  |  | 28.5 |  |  | 55.8 |  |  | — |
Aerospace & Defense | 79.0 |  |  | 0.1 |  |  | 78.9 |  |  | — |
Retail & Consumer | 95.0 |  |  | 70.5 |  |  | 24.5 |  |  | — |
Oil & Gas | 73.4 |  |  | 71.2 |  |  | 2.2 |  |  | — |
Other | 166.2 |  |  | 100.2 |  |  | 66.0 |  |  | — |
Total direct sales | 1,435.3 |  |  | 640.4 |  |  | 478.8 |  |  | 316.1 |
Distributors | 83.5 |  |  | 35.3 |  |  | 44.8 |  |  | 3.4 |
Total | $ | 1,518.8 |  |  | $ | 675.7 |  |  | $ | 523.6 |  |  | $ | 319.5 |
(a) Direct sales by end market include sales made through third-party distributors where we have visibility to the end customer.

17

Table of Contents
Disaggregation of revenue for the three-month period ended June 28, 2024 is presented as follows ($ in millions):

| Total |  | Intelligent Operating Solutions |  | Precision Technologies |  | Advanced Healthcare Solutions
Sales: |  |  |  |  |  |  |
Sales of products and software | $ | 1,308.9 |  |  | $ | 563.3 |  |  | $ | 490.3 |  |  | $ | 255.3 |
Sales of services | 243.5 |  |  | 113.7 |  |  | 61.5 |  |  | 68.3 |
Total | $ | 1,552.4 |  |  | $ | 677.0 |  |  | $ | 551.8 |  |  | $ | 323.6 |
Geographic: |  |  |  |  |  |  |
United States | $ | 840.3 |  |  | $ | 380.8 |  |  | $ | 281.0 |  |  | $ | 178.5 |
China | 165.1 |  |  | 53.2 |  |  | 86.6 |  |  | 25.3 |
All other | 547.0 |  |  | 243.0 |  |  | 184.2 |  |  | 119.8 |
Total | $ | 1,552.4 |  |  | $ | 677.0 |  |  | $ | 551.8 |  |  | $ | 323.6 |
End markets:(a) |  |  |  |  |  |  |
Direct sales: |  |  |  |  |  |  |
Healthcare | $ | 368.9 |  |  | $ | 11.1 |  |  | $ | 51.5 |  |  | $ | 306.3 |
Industrial & Manufacturing | 329.7 |  |  | 236.0 |  |  | 89.1 |  |  | 4.6 |
Government | 142.2 |  |  | 80.3 |  |  | 52.6 |  |  | 9.3 |
Utilities & Power | 104.1 |  |  | 48.8 |  |  | 55.3 |  |  | — |
Communications, Electronics & Semiconductor | 94.5 |  |  | 25.5 |  |  | 69.0 |  |  | — |
Aerospace & Defense | 83.4 |  |  | 0.1 |  |  | 83.3 |  |  | — |
Retail & Consumer | 80.6 |  |  | 65.5 |  |  | 15.1 |  |  | — |
Oil & Gas | 72.1 |  |  | 69.3 |  |  | 2.8 |  |  | — |
Other | 175.9 |  |  | 100.0 |  |  | 75.9 |  |  | — |
Total direct sales | 1,451.4 |  |  | 636.6 |  |  | 494.6 |  |  | 320.2 |
Distributors | 101.0 |  |  | 40.4 |  |  | 57.2 |  |  | 3.4 |
Total | $ | 1,552.4 |  |  | $ | 677.0 |  |  | $ | 551.8 |  |  | $ | 323.6 |
(a) Direct sales by end market include sales made through third-party distributors where we have visibility to the end customer.

18

Table of Contents
Disaggregation of revenue for the six-month period ended June 27, 2025 is presented as follows ($ in millions):

| Total |  | Intelligent Operating Solutions |  | Precision Technologies |  | Advanced Healthcare Solutions
Sales: |  |  |  |  |  |  |
Sales of products and software | $ | 2,525.8 |  |  | $ | 1,131.6 |  |  | $ | 908.5 |  |  | $ | 485.7 |
Sales of services | 467.2 |  |  | 215.5 |  |  | 115.7 |  |  | 136.0 |
Total | $ | 2,993.0 |  |  | $ | 1,347.1 |  |  | $ | 1,024.2 |  |  | $ | 621.7 |
Geographic: |  |  |  |  |  |  |
United States | $ | 1,631.1 |  |  | $ | 756.6 |  |  | $ | 518.8 |  |  | $ | 355.7 |
China | 317.0 |  |  | 109.3 |  |  | 158.4 |  |  | 49.3 |
All other | 1,044.9 |  |  | 481.2 |  |  | 347.0 |  |  | 216.7 |
Total | $ | 2,993.0 |  |  | $ | 1,347.1 |  |  | $ | 1,024.2 |  |  | $ | 621.7 |
End markets:(a) |  |  |  |  |  |  |
Direct sales: |  |  |  |  |  |  |
Healthcare | $ | 701.5 |  |  | $ | 21.1 |  |  | $ | 92.4 |  |  | $ | 588.0 |
Industrial & Manufacturing | 665.4 |  |  | 471.3 |  |  | 185.1 |  |  | 9.0 |
Government | 254.4 |  |  | 151.3 |  |  | 85.1 |  |  | 18.0 |
Utilities & Power | 223.5 |  |  | 98.0 |  |  | 125.5 |  |  | — |
Communications, Electronics & Semiconductor | 164.8 |  |  | 57.7 |  |  | 107.1 |  |  | — |
Aerospace & Defense | 153.2 |  |  | 0.2 |  |  | 153.0 |  |  | — |
Retail & Consumer | 180.1 |  |  | 137.9 |  |  | 42.2 |  |  | — |
Oil & Gas | 145.5 |  |  | 141.6 |  |  | 3.9 |  |  | — |
Other | 333.8 |  |  | 196.0 |  |  | 137.8 |  |  | — |
Total direct sales | 2,822.2 |  |  | 1,275.1 |  |  | 932.1 |  |  | 615.0 |
Distributors | 170.8 |  |  | 72.0 |  |  | 92.1 |  |  | 6.7 |
Total | $ | 2,993.0 |  |  | $ | 1,347.1 |  |  | $ | 1,024.2 |  |  | $ | 621.7 |
(a) Direct sales by end market include sales made through third-party distributors where we have visibility to the end customer.

19

Table of Contents
Disaggregation of revenue for the six-month period ended June 28, 2024 is presented as follows ($ in millions):

| Total |  | Intelligent Operating Solutions |  | Precision Technologies |  | Advanced Healthcare Solutions
Sales: |  |  |  |  |  |  |
Sales of products and software | $ | 2,608.8 |  |  | $ | 1,130.2 |  |  | $ | 990.9 |  |  | $ | 487.7 |
Sales of services | 468.1 |  |  | 212.5 |  |  | 119.9 |  |  | 135.7 |
Total | $ | 3,076.9 |  |  | $ | 1,342.7 |  |  | $ | 1,110.8 |  |  | $ | 623.4 |
Geographic: |  |  |  |  |  |  |
United States | $ | 1,630.2 |  |  | $ | 730.3 |  |  | $ | 555.1 |  |  | $ | 344.8 |
China | 341.4 |  |  | 120.3 |  |  | 169.5 |  |  | 51.6 |
All other | 1,105.3 |  |  | 492.1 |  |  | 386.2 |  |  | 227.0 |
Total | $ | 3,076.9 |  |  | $ | 1,342.7 |  |  | $ | 1,110.8 |  |  | $ | 623.4 |
End markets:(a) |  |  |  |  |  |  |
Direct sales: |  |  |  |  |  |  |
Healthcare | $ | 706.1 |  |  | $ | 22.4 |  |  | $ | 94.7 |  |  | $ | 589.0 |
Industrial & Manufacturing | 680.0 |  |  | 478.2 |  |  | 192.6 |  |  | 9.2 |
Government | 268.4 |  |  | 149.8 |  |  | 100.2 |  |  | 18.4 |
Utilities & Power | 206.0 |  |  | 98.0 |  |  | 108.0 |  |  | — |
Communications, Electronics & Semiconductor | 184.9 |  |  | 53.4 |  |  | 131.5 |  |  | — |
Aerospace & Defense | 166.8 |  |  | 0.2 |  |  | 166.6 |  |  | — |
Retail & Consumer | 157.4 |  |  | 127.2 |  |  | 30.2 |  |  | — |
Oil & Gas | 144.8 |  |  | 138.8 |  |  | 6.0 |  |  | — |
Other | 364.1 |  |  | 195.9 |  |  | 168.2 |  |  | — |
Total direct sales | 2,878.5 |  |  | 1,263.9 |  |  | 998.0 |  |  | 616.6 |
Distributors | 198.4 |  |  | 78.8 |  |  | 112.8 |  |  | 6.8 |
Total | $ | 3,076.9 |  |  | $ | 1,342.7 |  |  | $ | 1,110.8 |  |  | $ | 623.4 |
(a) Direct sales by end market include sales made through third-party distributors where we have visibility to the end customer.

NOTE 7. INCOME TAXES
Our effective tax rate for the three and six-month period ended June 27, 2025 was 13.2% and 14.0%, respectively, as compared to 14.7% and 13.0%, respectively, for the three and six-month period ended June 28, 2024. The decrease in the effective tax rate for the three-month period ended June 27, 2025 as compared to the three-month period ended June 28, 2024 was primarily related to a change in mix of earnings in the comparable prior year period. The increase in the effective tax rate for the six-month period ended June 27, 2025 as compared to the six-month period ended June 28, 2024 was primarily related to a discrete tax credit in the comparable prior year period from cash repatriation.
Our effective tax rate for the three and six-month period ended June 27, 2025 , differs from the U.S. federal statutory rate of 21% due primarily to the impact of credits and deductions provided by law, including those associated with state income taxes, and changes in our uncertain tax position reserves.
NOTE 8. STOCK-BASED COMPENSATION
The 2016 Stock Incentive Plan (the “Stock Plan”), provides for the grant of stock appreciation rights, restricted stock units, and performance stock units (collectively, “Stock Awards”), stock options, or any other stock-based award. As of June 27, 2025, approximately 10 million shares of our common stock were available for subsequent issuance under the Stock Plan. For a full description of our Stock Plan, refer to Note 14 of our 2024 Annual Report on Form 10-K.
20

Table of Contents
Stock-based compensation has been recognized as a component of Selling, general and administrative expenses in the Consolidated Condensed Statements of Earnings based on the portion of the awards that are ultimately expected to vest.
The following summarizes the components of our stock-based compensation expense under the Stock Plan ($ in millions):

| Three Months Ended |  | Six Months Ended
| June 27, 2025 |  | June 28, 2024 |  | June 27, 2025 |  | June 28, 2024
Stock Awards: |  |  |  |  |  |  |
Pretax compensation expense | $ | 22.4 |  |  | $ | 15.6 |  |  | $ | 43.3 |  |  | $ | 37.1 |
Income tax benefit | (3.3) |  |  | (2.9) |  |  | (6.7) |  |  | (5.5) |
Stock Award expense, net of income taxes | 19.1 |  |  | 12.7 |  |  | 36.6 |  |  | 31.6 |
Stock options: |  |  |  |  |  |  |
Pretax compensation expense | 5.0 |  |  | 8.6 |  |  | 11.6 |  |  | 16.0 |
Income tax benefit | (0.6) |  |  | (1.2) |  |  | (1.6) |  |  | (2.3) |
Stock option expense, net of income taxes | 4.4 |  |  | 7.4 |  |  | 10.0 |  |  | 13.7 |
Total stock-based compensation: |  |  |  |  |  |  |
Pretax compensation expense | 27.4 |  |  | 24.2 |  |  | 54.9 |  |  | 53.1 |
Income tax benefit | (3.9) |  |  | (4.1) |  |  | (8.3) |  |  | (7.8) |
Total stock-based compensation expense, net of income taxes | $ | 23.5 |  |  | $ | 20.1 |  |  | $ | 46.6 |  |  | $ | 45.3 |

The following summarizes the unrecognized compensation cost for the Stock Awards and stock options as of June 27, 2025. This compensation cost is expected to be recognized over a weighted average period of approximately two years, representing the remaining service period related to the awards. Future compensation amounts will be adjusted for any changes in estimated forfeitures ($ in millions):

Stock Awards | $ | 167.9 |
Stock options | 39.9 |
Total unrecognized compensation cost | $ | 207.8 |

Ralliant Separation
Subsequent to quarter-end, in connection with the Separation and in accordance with the employee matters agreement between Fortive and Ralliant, the Company has made certain adjustments to the exercise price and the number of stock-based awards with the intention of preserving the intrinsic value of the awards immediately prior to the Separation. Stock-based awards of Fortive held by employees who transferred to Ralliant in the Separation were converted into stock-based awards of Ralliant issued under Ralliant’s stock plan.
NOTE 9. COMMITMENTS AND CONTINGENCIES
For a description of our litigation and contingencies and additional information about our leases, refer to Note 13 and Note 8, respectively, in our 2024 Annual Report on Form 10-K.
Warranty
We generally accrue estimated warranty costs at the time of sale. In general, manufactured products are warranted against defects in material and workmanship when properly used for their intended purpose, installed correctly, and appropriately maintained. Warranty period terms depend on the nature of the product and range from 90 days up to the life of the product. The amount of the accrued warranty liability is determined based on historical information such as past experience, product failure rates or number of units repaired, estimated cost of material and labor, and, in certain instances, estimated property damage. The accrued warranty liability is reviewed on a quarterly basis and may be adjusted as additional information regarding expected warranty costs becomes known. During the three and six-month periods ended June 27, 2025 and June 28, 2024, warranty related activity was immaterial.
Leases
Operating lease costs for each period are presented as follows ($ in millions):
21

Table of Contents

| Three Months Ended |  | Six Months Ended
| June 27, 2025 |  | June 28, 2024 |  | June 27, 2025 |  | June 28, 2024
Operating lease costs | $ | 11.5 |  |  | $ | 12.5 |  |  | $ | 24.1 |  |  | $ | 25.1 |

Supplemental balance sheet and cash flow information related to operating leases for each period is presented as follows ($ in millions):

| As of
| June 27, 2025 |  | December 31, 2024
Right-of-use (“ROU”) assets (a) | $ | 159.3 |  |  | $ | 164.2 |
Operating lease liabilities (b) | 165.1 |  |  | 169.6 |
(a) ROU assets are recorded in the Consolidated Condensed Balance Sheets within Other assets.
(b) Operating lease liabilities are recorded in the Consolidated Condensed Balance Sheets within Accrued expenses and other current liabilities, and Other long-term liabilities.

| Six Months Ended
| June 27, 2025 |  | June 28, 2024
Cash paid for operating leases | $ | 23.7 |  |  | $ | 24.2 |
ROU assets obtained in exchange for operating lease obligations | 0.6 |  |  | 9.7 |

NOTE 10. NET EARNINGS PER SHARE
Basic net earnings per share (“EPS”) is calculated by dividing net earnings attributable to common stockholders by the weighted average number of shares of common stock outstanding for the applicable period. Diluted EPS is similarly calculated, except that the calculation includes the dilutive effect of the assumed issuance of shares under stock-based compensation plans under the treasury stock method, except where the inclusion of such shares would have an anti-dilutive impact. Anti-dilutive options excluded from the diluted EPS calculation for the three and six-month periods ended June 27, 2025 were 2.2 million and 1.9 million, respectively, and were 1.3 million and 1.2 million, respectively, for the three and six-month periods ended June 28, 2024.
Information related to the calculation of net earnings per share of common stock is summarized as follows ($ and shares in millions, except per share amounts):

| Three Months Ended |  | Six Months Ended
| June 27, 2025 |  | June 28, 2024 |  | June 27, 2025 |  | June 28, 2024
Numerator |  |  |  |  |  |  |
Net earnings | $ | 166.6 |  |  | $ | 195.1 |  |  | $ | 338.5 |  |  | $ | 402.5 |
Denominator |  |  |  |  |  |  |
Weighted average common shares outstanding used in basic earnings per share | 339.6 |  |  | 351.3 |  |  | 340.3 |  |  | 351.5 |
Incremental common shares from: |  |  |  |  |  |  |
Assumed exercise of dilutive options and vesting of dilutive Stock Awards | 2.1 |  |  | 3.5 |  |  | 2.9 |  |  | 3.9 |
Weighted average common shares outstanding used in diluted earnings per share | 341.7 |  |  | 354.8 |  |  | 343.2 |  |  | 355.4 |
Net earnings per common share - Basic | $ | 0.49 |  |  | $ | 0.56 |  |  | $ | 0.99 |  |  | $ | 1.15 |
Net earnings per common share - Diluted | $ | 0.49 |  |  | $ | 0.55 |  |  | $ | 0.99 |  |  | $ | 1.13 |

22

Table of Contents
General Share Repurchase Program
On February 17, 2022, the Company's Board of Directors approved a share repurchase program authorizing the Company to repurchase up to 20 million shares of the Company's outstanding common stock from time to time on the open market or in privately negotiated transactions. On January 23, 2024 and May 27, 2025, the Company’s Board of Directors increased the number of shares authorized under the share repurchase program by an additional 11 million and 15.6 million shares, respectively. As of June 27, 2025, there were 19.2 million shares remaining authorized under the share repurchase program. There is no expiration date for the repurchase program, and the timing and amount of repurchases under the program are determined by the Company's management based on market conditions and other factors. The repurchase program may be suspended or discontinued at any time by the Board of Directors.
During the three and six-month period ended June 27, 2025, the Company purchased 1.9 million and 4.4 million shares of its common stock at an average share price of $71.15 and $76.76, respectively. During the three and six-month periods ended June 28, 2024, the Company purchased 2 million shares of its common stock at an average share price of $76.43. Our common stock repurchases in excess of issuances are subject to a 1% excise tax enacted by the Inflation Reduction Act. Any excise tax incurred is recorded as part of the cost basis of the shares acquired within Common stock repurchases in the Consolidated Condensed Statement of Equity. The payment of the excise tax is recorded within Repurchase of common shares in the Consolidated Condensed Statement of Cash Flows.
Special Purpose Share Repurchase Program
On May 27, 2025, in connection with the Separation, the Company’s Board of Directors adopted a separate special purpose share repurchase program (the “Special Purpose Share Repurchase Program”) under which Fortive may purchase up to $550 million in Fortive’s common stock exclusively from the proceeds of the Ralliant Dividend, together with any other cash received by Fortive from Ralliant in connection with the Separation (collectively, the “Ralliant Cash Proceeds”). Repurchases of shares of Fortive common stock using the Ralliant Cash Proceeds will only be made through the Special Purpose Share Repurchase Program.
NOTE 11. SEGMENT INFORMATION
We report our results in three separate business segments consisting of Intelligent Operating Solutions, Precision Technologies, and Advanced Healthcare Solutions. We determine our business segments based on the identification of segment managers and similarities in products, end markets, economic characteristics, technologies, and services, as well as the financial data utilized by the Company's chief executive officer. The Company's chief operating decision maker ("CODM") is the chief executive officer.
The CODM uses gross profit and operating profit at the segment level to assess performance and allocate resources, including merger and acquisition targets. The CODM also compares the actual results to expectations in assessing the performance of the segments. Gross profit represents total revenue less total cost of sales. Operating expenses generally include selling, general and administrative expenses, and research and development expenses. Depreciation expense is allocated between Cost of sales and Selling, general, and administrative expenses. Amortization expense is recorded within Selling, general, and administrative expenses. Operating profit represents gross profit less operating expenses. The identifiable assets by segment are those used in each segment’s operations. Inter-segment amounts are not significant and are eliminated in the combined totals. Unallocated costs and other costs are not considered part of our evaluation of reportable segment operating performance.
The IOS segment provides advanced instrumentation, software and services to tens of thousands of customers enabling their mission-critical workflows. These offerings include professional instrumentation including electrical test & measurement equipment, facility and asset lifecycle software applications, connected worker safety and compliance solutions across a range of vertical end markets, including manufacturing, process industries, healthcare, utilities and power, communications and electronics, among others. Typical users of these safety, productivity and sustainability solutions include electrical engineers, electricians, electronic technicians, EHS professionals, network technicians, facility managers, first-responders, and maintenance professionals.
The PT segment helps solve tough technical challenges to speed breakthroughs in a wide range of applications, from food and beverage production and manufacturing to next-generation electric vehicles and clean energy, as our customers seek new test solutions to enable the electrification and connectivity of everything. Our expertise in materials, methods and measurements are reflected in our electrical test & measurement and sensing and material technologies offered to a broad set of customers and vertical end markets, including industrial, power and energy, automotive, medical equipment, food and beverage, aerospace and defense, semiconductor, and other general industries. Customers for these products and services include design engineers for advanced electronic devices and equipment, process and quality engineers focused on improved process capability and
23

Table of Contents
productivity, facility maintenance managers driving increased uptime, and other customers for whom precise measurement, reliability, and compliance are critical in their applications.
The AHS segment supplies critical workflow solutions enabling healthcare providers to deliver exceptional patient care more efficiently. Our offerings include instrument sterilization solutions, instrument tracking, biomedical test tools, radiation detection and safety monitoring, and end-to-end clinical productivity software and solutions. Our healthcare offerings help ensure critical safety standards are met, instruments and operating rooms are working at peak performance, and complex procedures are followed accurately in these mission-critical healthcare environments.
Segment results for the three-month period ended June 27, 2025 are shown below ($ in millions):

| Total |  | Intelligent Operating Solutions |  | Precision Technologies |  | Advanced Healthcare Solutions |  | Unallocated Corporate Costs and Other
Sales | $ | 1,518.8 |  |  | $ | 675.7 |  |  | $ | 523.6 |  |  | $ | 319.5 |  |  | $ | — |
Cost of sales | (623.1) |  |  | (231.8) |  |  | (261.3) |  |  | (130.0) |  |  | — |
Gross profit | 895.7 |  |  | 443.9 |  |  | 262.3 |  |  | 189.5 |  |  | — |
Operating expenses (a) | (673.5) |  |  | (277.2) |  |  | (169.1) |  |  | (150.4) |  |  | (76.8) |
Operating profit (loss) | 222.2 |  |  | 166.7 |  |  | 93.2 |  |  | 39.1 |  |  | (76.8) |
Non-operating income (expense), net |  |  |  |  |  |  |  |  |
Interest expense, net | (32.1) |  |  | — |  |  | — |  |  | — |  |  | (32.1) |
Other non-operating expense, net | 1.9 |  |  | — |  |  | — |  |  | — |  |  | 1.9 |
Earnings before income taxes | $ | 192.0 |  |  | $ | 166.7 |  |  | $ | 93.2 |  |  | $ | 39.1 |  |  | $ | (107.0) |
Depreciation and amortization expenses | $ | (137.8) |  |  | $ | (58.4) |  |  | $ | (28.7) |  |  | $ | (50.4) |  |  | $ | (0.3) |
Capital expenditure | $ | (36.7) |  |  | $ | (20.1) |  |  | $ | (11.6) |  |  | $ | (4.9) |  |  | $ | (0.1) |
(a) Unallocated Corporate Costs and Other included $41 million of Separation-related costs. Refer to Note 2 for further detail.

Segment results for the three-month period ended June 28, 2024 are shown below ($ in millions):

| Total |  | Intelligent Operating Solutions |  | Precision Technologies |  | Advanced Healthcare Solutions |  | Unallocated Corporate Costs and Other
Sales | $ | 1,552.4 |  |  | $ | 677.0 |  |  | $ | 551.8 |  |  | $ | 323.6 |  |  | $ | — |
Cost of sales | (624.1) |  |  | (221.7) |  |  | (266.3) |  |  | (136.1) |  |  | — |
Gross profit | 928.3 |  |  | 455.3 |  |  | 285.5 |  |  | 187.5 |  |  | — |
Operating expenses | (626.5) |  |  | (282.1) |  |  | (170.2) |  |  | (147.3) |  |  | (26.9) |
Operating profit (loss) | 301.8 |  |  | 173.2 |  |  | 115.3 |  |  | 40.2 |  |  | (26.9) |
Non-operating income (expense), net |  |  |  |  |  |  |  |  |
Interest expense, net | (38.7) |  |  | — |  |  | — |  |  | — |  |  | (38.7) |
Loss from divestiture (a) | (25.6) |  |  | — |  |  | — |  |  | — |  |  | (25.6) |
Other non-operating expense, net | (8.8) |  |  | — |  |  | — |  |  | — |  |  | (8.8) |
Earnings before income taxes | $ | 228.7 |  |  | $ | 173.2 |  |  | $ | 115.3 |  |  | $ | 40.2 |  |  | $ | (100.0) |
Depreciation and amortization expenses | $ | (136.5) |  |  | $ | (57.1) |  |  | $ | (28.8) |  |  | $ | (50.4) |  |  | $ | (0.2) |
Capital expenditure | $ | (29.2) |  |  | $ | (14.9) |  |  | $ | (9.6) |  |  | $ | (3.1) |  |  | $ | (1.6) |
(a) Refer to Note 1 for further detail on Loss from divestiture.

24

Table of Contents
Segment results for the six-month period ended June 27, 2025 are shown below ($ in millions):

| Total |  | Intelligent Operating Solutions |  | Precision Technologies |  | Advanced Healthcare Solutions |  | Unallocated Corporate Costs and Other
Sales | $ | 2,993.0 |  |  | $ | 1,347.1 |  |  | $ | 1,024.2 |  |  | $ | 621.7 |  |  | $ | — |
Cost of sales | (1,216.4) |  |  | (455.0) |  |  | (507.3) |  |  | (254.1) |  |  | — |
Gross profit | 1,776.6 |  |  | 892.1 |  |  | 516.9 |  |  | 367.6 |  |  | — |
Operating expenses (a) | (1,320.8) |  |  | (551.7) |  |  | (336.4) |  |  | (302.2) |  |  | (130.5) |
Operating profit (loss) | 455.8 |  |  | 340.4 |  |  | 180.5 |  |  | 65.4 |  |  | (130.5) |
Non-operating income (expense), net |  |  |  |  |  |  |  |  |
Interest expense, net | (64.1) |  |  | — |  |  | — |  |  | — |  |  | (64.1) |
Other non-operating expense, net | 1.7 |  |  | — |  |  | — |  |  | — |  |  | 1.7 |
Earnings before income taxes | $ | 393.4 |  |  | $ | 340.4 |  |  | $ | 180.5 |  |  | $ | 65.4 |  |  | $ | (192.9) |
Depreciation and amortization expenses | $ | (272.7) |  |  | $ | (116.3) |  |  | $ | (55.9) |  |  | $ | (99.9) |  |  | $ | (0.6) |
Capital expenditure | $ | (63.4) |  |  | $ | (37.0) |  |  | $ | (17.2) |  |  | $ | (8.9) |  |  | $ | (0.3) |
(a) Unallocated Corporate Costs and Other included $64 million of Separation-related costs. Refer to Note 2 for further detail.

Segment results for the six-month period ended June 28, 2024 are shown below ($ in millions):

| Total |  | Intelligent Operating Solutions |  | Precision Technologies |  | Advanced Healthcare Solutions |  | Unallocated Corporate Costs and Other
Sales | $ | 3,076.9 |  |  | $ | 1,342.7 |  |  | $ | 1,110.8 |  |  | $ | 623.4 |  |  | $ | — |
Cost of sales | (1,244.4) |  |  | (444.1) |  |  | (539.0) |  |  | (261.3) |  |  | — |
Gross profit | 1,832.5 |  |  | 898.6 |  |  | 571.8 |  |  | 362.1 |  |  | — |
Operating expenses | (1,291.6) |  |  | (561.3) |  |  | (370.5) |  |  | (294.4) |  |  | (65.4) |
Gain on sale of property (a) | 63.1 |  |  | — |  |  | 63.1 |  |  | — |  |  | — |
Operating profit (loss) | 604.0 |  |  | 337.3 |  |  | 264.4 |  |  | 67.7 |  |  | (65.4) |
Non-operating income (expense), net |  |  |  |  |  |  |  |  |
Interest expense, net | (82.7) |  |  | — |  |  | — |  |  | — |  |  | (82.7) |
Loss from divestiture (a) | (25.6) |  |  | — |  |  | — |  |  | — |  |  | (25.6) |
Other non-operating expense, net | (33.0) |  |  | — |  |  | — |  |  | — |  |  | (33.0) |
Earnings before income taxes | $ | 462.7 |  |  | $ | 337.3 |  |  | $ | 264.4 |  |  | $ | 67.7 |  |  | $ | (206.7) |
Depreciation and amortization expenses | $ | (273.3) |  |  | $ | (114.4) |  |  | $ | (58.2) |  |  | $ | (100.5) |  |  | $ | (0.2) |
Capital expenditure | $ | (55.6) |  |  | $ | (33.6) |  |  | $ | (13.7) |  |  | $ | (5.8) |  |  | $ | (2.5) |
(a) Refer to Note 1 for further detail on Gain on sale of property and Loss from divestiture.

25

Table of Contents
Segment Assets:

| As of
($ in millions) | June 27, 2025 |  | December 31, 2024 |  |
Intelligent Operating Solutions | $ | 6,343.2 |  |  | $ | 6,320.1 |  |  |
Precision Technologies | 4,947.6 |  |  | 4,691.9 |  |  |
Advanced Healthcare Solutions | 4,947.1 |  |  | 5,008.6 |  |  |
Total segment assets | 16,237.9 |  |  | 16,020.6 |  |  |
Other (a) | 2,006.3 |  |  | 995.5 |  |  |
Total assets | $ | 18,244.2 |  |  | $ | 17,016.1 |  |  |
(a) Other represents corporate assets which consist primarily of cash, property, plant, and equipment, and net deferred income tax assets. |  |

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Fortive Corporation (“Fortive,” the “Company,” “we,” “us,” or “our”) is a provider of essential technologies for connected workflow solutions across a range of attractive end-markets. Our strategic segments - Intelligent Operating Solutions (“IOS”), Precision Technologies (“PT”), and Advanced Healthcare Solutions (“AHS”) - include well-known brands with leading positions in their markets. Our businesses design, develop, manufacture, and service professional and engineered products, software, and services, building upon leading brand names, innovative technologies, and significant market positions. We are headquartered in Everett, Washington and have a workforce of more than 18,000 research and development, manufacturing, sales, distribution, service, and administrative professionals in more than 50 countries around the world.
This Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is designed to provide a reader of our financial statements with a narrative from the perspective of management. The following discussion should be read in conjunction with the MD&A and consolidated financial statements included in our 2024 Annual Report on Form 10-K. Our MD&A is divided into five sections:
•Information Relating to Forward-Looking Statements
•Overview
•Results of Operations
•Liquidity and Capital Resources
•Critical Accounting Estimates
INFORMATION RELATING TO FORWARD-LOOKING STATEMENTS
Certain statements included or incorporated by reference in this quarterly report, in other documents we file with or furnish to the Securities and Exchange Commission (“SEC”), in our press releases, webcasts, conference calls, materials delivered to shareholders and other communications, are “forward-looking statements” within the meaning of the United States federal securities laws. All statements other than historical factual information are forward-looking statements, including without limitation statements regarding: projections of revenue, expenses, profit, profit margins, tax rates, tax provisions, cash flows, pension and benefit obligations and funding requirements, our liquidity position or other financial measures; impact of government actions, including tariffs, other trade policies, government spending and tax laws; management’s plans and strategies for future operations, including statements relating to anticipated operating performance, cost reductions, restructuring activities, new product and service developments, competitive strengths or market position, acquisitions, divestitures, strategic opportunities, stock repurchases, and dividends; growth, declines and other trends in markets we sell into, including the expected impact of trade and tariff policies; new or modified laws, regulations and accounting pronouncements; outstanding claims, legal proceedings, tax audits and assessments and other contingent liabilities; foreign currency exchange rates and fluctuations in those rates; general economic and capital markets conditions, including expected impact of inflation or interest rate changes; impact of geopolitical events and other hostilities; the timing of any of the foregoing; assumptions underlying any of the foregoing; and any other statements that address events or developments that we intend or believe will or may occur in the future. Terminology, such as “believe,” “anticipate,” “should,” “could,” “intend,” “will,” “plan,” “expect,” “estimate,” “project,” “target,” “may,” “possible,” “potential,” “forecast” and “positioned” and similar references to future periods, are intended to identify forward-looking statements, although not all forward-looking statements are accompanied by such words.
26

Table of Contents
Forward-looking statements are based on assumptions and assessments made by our management in light of their experience and perceptions of historical trends, current conditions, expected future developments, and other factors they believe to be appropriate. Forward-looking statements are not guarantees of future performance and actual results may differ materially from the results, developments and business decisions contemplated by our forward-looking statements. Accordingly, you should not place undue reliance on any such forward-looking statements. Important factors that could cause actual results to differ materially from those envisaged in the forward-looking statements include, among others, the following:
Risk Related to Our Business Operations
•Conditions in the global economy, the markets we serve, and the financial markets may adversely affect our business and financial results.
•If we cannot adjust our manufacturing capacity, supply chain management or the purchases required for our manufacturing activities to reflect changes in market conditions, customer demand and supply chain disruptions, our profitability may suffer. In addition, our reliance upon sole or limited sources of supply for certain materials, components, and services could cause production interruptions, delays and inefficiencies.
•Our financial results are subject to fluctuations in the cost and availability of commodities or components that we use in our operations.
•Our growth could suffer if the markets into which we sell our products and services decline, do not grow as anticipated, or experience cyclicality.
•We face intense competition and if we are unable to compete effectively, we may experience decreased demand and decreased market share. Even if we compete effectively, we may be required to reduce prices for our products and services.
•Our growth depends in part on the timely development and commercialization and customer acceptance of new and enhanced products and services based on technological innovation.
•Our ability to attract, develop, and retain senior leaders and other key employees is critical to our success.
•Disruptions in, or breaches in security of, our information technology systems have adversely affected, and in the future could adversely affect, our business.
•Defects and unanticipated use or inadequate disclosure with respect to our products (including software) or services could adversely affect our business, reputation, and financial results.
•Adverse changes in our relationships with, or the financial condition, performance, purchasing patterns, or inventory levels of, key distributors and other channel partners could adversely affect our financial results.
•Our restructuring activities could have long-term adverse effects on our business.
•Work stoppages, works council campaigns, and other labor disputes could adversely impact our productivity and results of operations.
•If we suffer loss to our facilities, supply chains, distribution systems, or information technology systems due to catastrophe or other events, our operations could be seriously harmed.
•If we do not or cannot adequately protect our intellectual property, or if third parties infringe our intellectual property rights, we may suffer competitive injury or expend significant resources enforcing our rights.
•Third parties may claim that we are infringing or misappropriating their intellectual property rights and we could suffer significant litigation expenses, losses, or licensing expenses or be prevented from selling products or services.
•We are subject to a variety of litigation and other legal and regulatory proceedings in the course of our business that could adversely affect our financial results.
•Climate change, or legal or regulatory measures to address climate change, may negatively affect us.
•We may use artificial intelligence in our business and in our products, and challenges with properly managing its use could result in reputational harm, competitive harm, and legal liability, and adversely affect our results of operations.
27

Table of Contents
Risk Related to our International Operations
•International economic, political, legal, trade policies, compliance, and business factors could negatively affect our financial results.
•Trade relations between the United States and other countries, including imposition of new or increased tariffs and related uncertainty thereof, could have a material adverse effect on our business and financial results.
•Foreign currency exchange rates, including the volatility thereof, may adversely affect our financial results.
Risk Related to Our Acquisitions, Investments, and Dispositions
•Any inability to consummate acquisitions at our anticipated rate and at appropriate prices, and to make appropriate investments that support our long-term strategy, could negatively impact our growth rate and stock price.
•Our acquisition of businesses, investments, joint ventures, and other strategic relationships could negatively impact our financial results.
•The indemnification provisions of acquisition agreements by which we have acquired companies may not fully protect us and as a result we may face unexpected liabilities.
•Divestitures or other dispositions could negatively impact our business, and contingent liabilities from businesses that we have sold could adversely affect our financial results.
•Potential indemnification liabilities to Ralliant Corporation (“Ralliant”) and Vontier Corporation (“Vontier”) pursuant to the respective separation agreements could materially and adversely affect our businesses, financial condition, results of operations, and cash flows.
Risk Related to Regulatory and Compliance Matters
•Changes in industry standards and governmental regulations may reduce demand for our products or services or increase our expenses.
•Our reputation, ability to do business, and financial results may be impaired by improper conduct by any of our employees, agents, or business partners.
•Our operations, products, and services expose us to the risk of environmental, health, and safety liabilities, costs, and violations that could adversely affect our reputation and financial results.
•Our businesses are subject to extensive regulation, including healthcare regulations; failure to comply with those regulations could adversely affect our financial results and our business, including our reputation.
Risk Related to Our Tax and Accounting Matters
•Changes in our effective tax rates or exposure to additional tax liabilities or assessments could affect our profitability. In addition, audits by tax authorities could result in additional tax payments for prior periods.
•We could incur significant liability if our separation from Danaher, our separation of our Automation and Specialty business, our separation of Ralliant, or our separation of Vontier (collectively, the “Separation Transactions”) is determined to be a taxable transaction.
•Changes in U.S. GAAP could adversely affect our reported financial results and may require significant changes to our internal accounting systems and processes.
•We may be required to recognize impairment charges for our goodwill and other intangible assets.
Risk Related to Our Financing Activities
•We have incurred a significant amount of debt, and our debt obligations, including the cost of such debt, will increase further if we incur additional debt and do not retire existing debt, our credit rating declines, or if the applicable interest rates rise.
See “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in this Quarterly Report on Form 10-Q for further discussion regarding reasons that actual results may differ materially from the
28

Table of Contents
results, developments, and business decisions contemplated by our forward-looking statements. Forward-looking statements speak only as of the date of the report, document, press release, webcast, call, materials or other communication in which they are made (or such earlier date as may be specified in such statement). We do not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.
OVERVIEW
General
Fortive is a multinational business with global operations with approximately 46% of our sales derived from customers outside the United States in 2024. As a company with global operations, our businesses are affected by worldwide, regional, and industry-specific economic, regulatory, and political factors. Our geographic and industry diversity, as well as the range of products, software, and services we offer, typically help limit the impact of any one industry or the economy of any single country (except for the United States) on our operating results. Given the broad range of products manufactured, software and services provided, and geographies served, we do not use any indices other than general economic trends to predict the overall outlook for the Company. Our individual businesses monitor key competitors and customers, including their sales, to the extent possible, to gauge relative performance and the outlook for the future.
As a result of our geographic and industry diversity, we face a variety of opportunities and challenges, including technological development in most of the markets we serve, the expansion and evolution of opportunities in growing markets, trends and costs associated with a global labor force, and consolidation of our competitors. We operate in a highly competitive business environment in most markets, and our long-term growth and profitability will depend, in particular, on our ability to expand our business across geographies and market segments, identify, consummate, and integrate appropriate acquisitions, develop innovative and differentiated new products, services, and software, expand and improve the effectiveness of our sales force, continue to reduce costs and improve operating efficiency and quality, attract relevant talent and retain, grow, and empower our talented workforce, and effectively address the demands of an increasingly regulated environment. We are making significant investments, organically and through acquisitions, to address technological change in the markets we serve and to improve our manufacturing, research and development, and customer-facing resources in order to be responsive to our customers throughout the world.
Segment Presentation
Prior to the separation of Ralliant Corporation on June 28, 2025, we operated and reported our results in three segments, IOS, PT, and AHS.
The IOS segment provides advanced instrumentation, software and services to tens of thousands of customers enabling their mission-critical workflows. The PT segment helps solve tough technical challenges to speed breakthroughs in a wide range of applications, from food and beverage production and manufacturing to next-generation electric vehicles and clean energy, as our customers seek new test solutions to enable the electrification and connectivity of everything. The AHS segment supplies critical workflow solutions enabling healthcare providers to deliver exceptional patient care more efficiently. Refer to Note 11 for further description of each segment.
In January 2024, we realigned Invetech from the AHS segment to the PT segment (the “Segment Realignment”) based on our strategic decision to divest the equipment design and manufacturing businesses of Invetech, while retaining the motion solution businesses (the “Motion Solution Business”) that are more closely aligned with the PT segment than the AHS segment. In June 2024, we divested and transferred ownership of Invetech, excluding the Motion Solution Business, to its management team (the “Invetech Divestiture”).
Non-GAAP Measures
In this report, references to sales from existing businesses (“core revenue”) refer to sales from operations calculated according to generally accepted accounting principles in the United States (“GAAP”) but excluding (1) the impact from acquired and divested businesses and (2) the impact of foreign currency translation. References to sales attributable to acquisitions or acquired businesses refer to GAAP sales from acquired businesses recorded prior to the first anniversary of the acquisition, less the amount of sales attributable to certain businesses or product lines that have been divested, or, at the time of reporting, are pending divestiture, but are not, and will not be, considered discontinued operations prior to the first anniversary of the divestiture. The portion of sales attributable to the impact of currency translation is calculated as the difference between (a) the period-to-period change in sales (excluding sales impact from acquired businesses) and (b) the period-to-period change in sales (excluding sales impact from acquired businesses) after applying the current period foreign exchange rates to the prior year
29

Table of Contents
period. Core revenue should be considered in addition to, and not as a replacement for or superior to, sales, and may not be comparable to similarly titled measures reported by other companies.
Management believes that reporting the non-GAAP financial measure of core revenue provides useful information to investors by helping identify underlying growth trends in our business and facilitating comparisons of our sales performance with our performance in prior and future periods and to our peers. We exclude the effect of acquisition and divestiture related items because the nature, size, and number of such transactions can vary dramatically from period to period and between us and our peers. We exclude the effect of currency translation from core revenue because the impact of currency translation is not under management’s control and is subject to volatility. Management believes the exclusion of the effect of acquisitions and divestitures and currency translation may facilitate the assessment of underlying business trends and may assist in comparisons of long-term performance. References to sales volume from existing businesses refer to the impact of both price and unit sales.
Precision Technologies Separation
On June 28, 2025 (the “Distribution Date”), the Company completed the separation (the “Separation” or the “PT Separation”) of its former Precision Technologies segment by distributing to Fortive shareholders on a pro rata basis all of the issued and outstanding common stock of Ralliant Corporation (“Ralliant”), the entity incorporated to hold the PT businesses. Beginning with the third quarter of 2025, the Company will classify Ralliant as a discontinued operation in its financial statements, as a result of the Separation. Refer to Note 2 for additional information.
Business Performance and Outlook
Business Performance for the Period Ended June 27, 2025
During the three and six-month period ended June 27, 2025 (the “quarter” or the “second quarter” and “year-to-date period,” respectively), our sales decreased by 2.2% and 2.7%, respectively.
The year-over-year decrease in the second quarter was a result of a 2.5% decrease in our core revenue, which was comprised of favorable pricing of 2.9% including countermeasures to mitigate the unfavorable tariffs impact, offset by volume declines of 5.4%. Additionally, there was a 0.9% increase from favorable foreign currency exchange rates and a 0.6% decrease from the effect of divested businesses.
Year-over-year decrease in the year-to-date period was primarily a result of a 2.1% decrease in our core revenue, which was comprised of favorable pricing of 2.4% including countermeasures to mitigate the unfavorable tariffs impact, offset by volume declines of 4.5%. Additionally, there was a 0.5% decrease from the effect of divested businesses.
Geographically, in the second quarter, the core revenue decline was driven primarily by market dynamics in Western Europe largely in the PT segment. North America and China also experienced softness in the quarter. Geographically, in the year-to-date period, the core revenue decline was again driven primarily by the PT segment in Western Europe. Further, declines in China were partially offset by growth in North America and Latin America. For further detail, refer to the Intelligent Operating Solutions, Precision Technologies, and Advanced Healthcare Solutions sections below.
Outlook
In 2025, the U.S. government began imposing tariffs on products from all countries and additional individualized reciprocal tariffs on certain countries. In response, China, in particular, and other countries have announced retaliatory tariffs against certain imports from the United States. Currently, certain of these tariffs have been temporarily paused until August of 2025. There may be additional changes to tariff levels, trade restrictions, and other aspects of global trade policy in the U.S. and other countries due to global trade negotiations and other factors. These changes to trade policies, retaliatory measures, and prolonged uncertainty in trade relationships negatively impact operations and financial results, including potential impairment of certain intangible assets, through resulting supply chain disruptions, delayed shipments, and increased operational complexities and costs. We continue to evaluate the impact of tariffs on our financial results, as the application and imposition of these tariffs remains unpredictable. For additional discussion of risks related to tariffs and trade relations, please refer to the risk factor, “Trade relations between the United States and other countries, including the imposition of new or increased tariffs and related uncertainty thereof, could have a material adverse effect on our business and financial results” in Part II, Item 1A. Risk Factors of the Quarterly Report on Form 10-Q for the fiscal quarter ended March 28, 2025.
30

Table of Contents
We also expect foreign exchange rates to remain volatile throughout the year, which could continue to impact our financial results. Additionally, our financial outlook is subject to various assumptions and risks, including but not limited to, ongoing geopolitical developments and events, uncertainties related to governmental policies on international trade and healthcare, monetary and fiscal policies, including the current uncertainty about the future relationship between the United States and other regions with respect to tariffs as mentioned above, trade policies, treaties, government regulations and sanctions, reductions in spending by the U.S. government as a result of the recently enacted One Big Beautiful Bill Act (“OBBBA”) and the formation of the Department of Government Efficiency, increased economic nationalism, macroeconomic conditions in the United States, China, and other critical regions, impact from our separation into two independent publicly traded companies, and the impact of inflationary dynamics on our expenses or our ability to realize price increases and/or competitiveness in our sales, interest rates, market conditions in key product segments, and elective surgery rates.
We continue to deploy the Fortive Business System (“FBS”), including tools and processes to leverage existing sourcing strategies and optimize production and logistics to actively manage these challenges and utilize pricing, cost and productivity actions and other countermeasures designed to offset the aforementioned dynamics. We continue to monitor these conditions and potential adverse global economic trends and sentiments, monetary and fiscal policies, international trade policies and relations between the U.S., China and other nations, and investment and taxation policy initiatives being considered in the United States and by the Organization for Economic Co-operation and Development (“OECD”), including incremental impacts of the Pillar Two initiative. In addition, we are continuing to assess the potential impact, including on our tax liabilities and our strategies, of the OBBBA. Refer to Income Taxes below for further detail on the OECD initiatives and the OBBBA.
RESULTS OF OPERATIONS
Sales Growth
The following table summarizes total aggregate year-over-year sales growth and the components thereof for the second quarter as compared to the comparable period of 2024:
Components of Sales Growth

| % Change Three Months Ended June 27, 2025 vs. Comparable 2024 Period |  | % Change Six Months Ended June 27, 2025 vs. Comparable 2024 Period
Total revenue growth (GAAP) | (2.2) | % |  | (2.7) | %
Excluding impact of: |  |  |
Divestitures | 0.6 | % |  | 0.5 | %
Currency exchange rates | (0.9) | % |  | 0.1 | %
Core revenue growth (Non-GAAP) | (2.5) | % |  | (2.1) | %

Operating Profit Margins
Operating profit margin was 14.6% for the second quarter, representing a decrease of 480 basis points as compared to 19.4% in the comparable period of 2024. Year-over-year changes in operating profit margin were comprised of the following:
•The year-over-year increase in price and gains from productivity measures through our FBS initiatives were offset by overall volume declines, higher employee compensation, and unfavorable impacts from tariffs net of countermeasures — unfavorable 170 basis points
•The year-over year effect of all other items was an unfavorable 310 basis points comprised of -270 basis points from Separation, acquisition, and divestiture-related costs, -55 basis points in discrete restructuring charges, +30 basis points from the net effect of divested businesses, and -15 basis points from amortization of existing businesses
Operating profit margin was 15.2% for the year-to-date period, yielding a decrease of 440 basis points as compared to 19.6% in the comparable period of 2024. Year-over-year changes in operating profit margin were comprised of the following:
•The year-over-year increase in price and gains from productivity measures were offset by volume declines, higher employee compensation, investments in growth initiatives, and the unfavorable impact from tariffs net of countermeasures — unfavorable 95 basis points
31

Table of Contents
•The year-over year effect of all other items was an unfavorable 345 basis points comprised of -205 basis points from the gain on sale of property in PT in 2024, -125 basis points from Separation, acquisition, and divestiture-related costs, -40 basis points in discrete restructuring charges, +40 basis points from the net effect of acquired and divested businesses, and -15 basis points from amortization of existing businesses
INTELLIGENT OPERATING SOLUTIONS
Selected Financial Data

| Three Months Ended |  | Six Months Ended
($ in millions) | June 27, 2025 |  | June 28, 2024 |  | June 27, 2025 |  | June 28, 2024
Sales | $ | 675.7 |  | $ | 677.0 |  | $ | 1,347.1 |  | $ | 1,342.7
Operating profit | 166.7 |  | 173.2 |  | 340.4 |  | 337.3
Depreciation | 11.8 |  | 9.9 |  | 23.1 |  | 19.6
Amortization | 46.6 |  | 47.2 |  | 93.2 |  | 94.8
Operating profit as a % of sales | 24.7 | % |  | 25.6 | % |  | 25.3 | % |  | 25.1 | %
Depreciation as a % of sales | 1.7 | % |  | 1.5 | % |  | 1.7 | % |  | 1.5 | %
Amortization as a % of sales | 6.9 | % |  | 7.0 | % |  | 6.9 | % |  | 7.1 | %

Components of Sales Growth

| % Change Three Months Ended June 27, 2025 vs. Comparable 2024 Period |  | % Change Six Months Ended June 27, 2025 vs. Comparable 2024 Period
Total revenue growth (GAAP) | (0.2) | % |  | 0.3 | %
Excluding impact of: |  |  |
Divestitures | 0.6 | % |  | 0.3 | %
Currency exchange rates | (0.8) | % |  | 0.2 | %
Core revenue growth (Non-GAAP) | (0.4) | % |  | 0.8 | %

The sales results in both the second quarter and year-to-date period were driven by favorable pricing of 2.3% and 2.0%, respectively, including countermeasures to mitigate unfavorable tariff impacts, and volume increases in gas detection offerings. These benefits were offset by modest declines in professional instrumentation. Additionally, foreign currency exchange rates impacted sales results as indicated above.
Geographically, in the second quarter, the core revenue decline was driven primarily by lower sales in China in professional instrumentation, partially offset by growth in Latin America from gas detection offerings. North America core revenue has remained stable despite tariff-related uncertainty and lower government procurement spend.
Geographically, in the year-to-date period, core revenue growth was driven primarily by expansion in North America across majority of the segment led by facility and asset lifecycle SaaS products and gas detection solutions, as well as Latin America from strong demand in professional instrumentation and gas detection. This growth was partially offset by declines in Western Europe and China from softening demand in certain product lines in professional instrumentation and certain software and services in facility and asset lifecycle applications.
Operating profit margin decreased 90 basis points during the second quarter as compared to the comparable period of 2024. Year-over-year changes in operating profit margin were comprised of the following:
•The year-over-year increase in price and efficiency gains achieved from productivity measures through our FBS initiatives were offset by a net decrease in sales volume in the segment, higher employee compensation, investments in growth initiatives, and the unfavorable impact from tariffs net of countermeasures — unfavorable 30 basis points
•The year-over year effect of all other items was an unfavorable 60 basis points comprised of -85 basis points in discrete restructuring charges, +15 basis points from acquisition and divestiture-related costs, and +10 basis points from amortization of existing businesses
32

Table of Contents
Operating profit margin increased 20 basis points during the year-to-date period, as compared to the comparable period of 2024. Year-over-year changes in operating profit margin comparisons were comprised of the following:
•Year-over-year increase from favorable pricing and efficiency gains achieved from productivity through our FBS initiatives were partially offset by a net decrease in sales volume, higher employee compensation, and unfavorable impact from tariffs net of countermeasures — favorable 60 basis points
•The year-over year effect of all other items was an unfavorable 40 basis points comprised of -70 basis points in discrete restructuring charges, +20 basis points from amortization from existing businesses, and +10 basis points from acquisition and divestiture-related costs
PRECISION TECHNOLOGIES
Selected Financial Data

| Three Months Ended |  | Six Months Ended
($ in millions) | June 27, 2025 |  | June 28, 2024 |  | June 27, 2025 |  | June 28, 2024
Sales | $ | 523.6 |  | $ | 551.8 |  | $ | 1,024.2 |  | $ | 1,110.8
Operating profit | 93.2 |  | 115.3 |  | 180.5 |  | 264.4
Depreciation | 6.8 |  | 7.9 |  | 13.7 |  | 16.2
Amortization | 21.9 |  | 20.9 |  | 42.2 |  | 42.0
Operating profit as a % of sales | 17.8 | % |  | 20.9 | % |  | 17.6 | % |  | 23.8 | %
Depreciation as a % of sales | 1.3 | % |  | 1.4 | % |  | 1.3 | % |  | 1.5 | %
Amortization as a % of sales | 4.2 | % |  | 3.8 | % |  | 4.1 | % |  | 3.8 | %

Components of Sales Growth

| % Change Three Months Ended June 27, 2025 vs. Comparable 2024 Period |  | % Change Six Months Ended June 27, 2025 vs. Comparable 2024 period
Total revenue growth (GAAP) | (5.1) | % |  | (7.8) | %
Excluding impact of: |  |  |
Divestitures | 1.0 | % |  | 1.0 | %
Currency exchange rates | (1.2) | % |  | (0.1) | %
Core revenue growth (Non-GAAP) | (5.3) | % |  | (6.9) | %

The sales results for the second quarter and year-to-date period were driven by favorable pricing of 3.5% and 2.6%, respectively, including countermeasures to mitigate unfavorable tariff impacts, and increased demand in the utilities sector for grid modernization. These benefits were offset by volume reductions in test and measurement, energetic materials, and certain industrial sensing products, as well as the Invetech Divestiture. Additionally, foreign currency exchange rates impacted sales results as indicated above.
Geographically, in the second quarter and the year-to-date period, core revenue declines were experienced in Western Europe, North America, and China, from slow downs in test and measurement amid tariff-related uncertainties and volume decline in energetic materials. These declines were partially by growth in Latin America from increased demand in the utilities sector for grid modernization.
Operating profit margin decreased 310 basis points for the second quarter as compared to the comparable period of 2024. Year-over-year changes in operating profit margin were comprised of the following:
•Year-over-year increase in price and gains from productivity measures through our FBS initiatives were offset by net volume reductions, higher compensation costs, and unfavorable impacts from tariffs net of countermeasures— unfavorable 320 basis points
•The year-over year effect of all other items was a favorable 10 basis points comprised of +70 basis points from the Invetech Divestiture, -40 basis points from amortization of existing businesses, -15 basis points from acquisition and divestiture-related costs, and -5 basis points in discrete restructuring charges
33

Table of Contents
Operating profit margin decreased 620 basis points during the year-to-date period as compared to the comparable period of 2024. Year-over-year changes in operating profit margins were comprised of the following:
•Year-over-year increase in price from existing businesses and gains from productivity measures through our FBS initiatives were offset by net volume reduction in the segment, higher compensation costs, and unfavorable impacts from tariffs net of countermeasures — unfavorable 350 basis points
•The year-over year effect of all other items was an unfavorable 270 basis points comprised of -570 from the gain on sale of property in 2024, +225 basis points from acquisition and divestiture-related costs, +115 basis points from the Invetech Divestiture and acquisition-related fair value adjustments, -30 basis points from amortization of existing businesses, and -10 basis points in discrete restructuring charges
ADVANCED HEALTHCARE SOLUTIONS
Selected Financial Data

| Three Months Ended |  | Six Months Ended
($ in millions) | June 27, 2025 |  | June 28, 2024 |  | June 27, 2025 |  | June 28, 2024
Sales | $ | 319.5 |  | $ | 323.6 |  | $ | 621.7 |  | $ | 623.4
Operating profit | 39.1 |  | 40.2 |  | 65.4 |  | 67.7
Depreciation | 5.3 |  | 5.1 |  | 10.2 |  | 10.2
Amortization | 45.1 |  | 45.3 |  | 89.7 |  | 90.3
Operating profit as a % of sales | 12.2 | % |  | 12.4 | % |  | 10.5 | % |  | 10.9 | %
Depreciation as a % of sales | 1.7 | % |  | 1.6 | % |  | 1.6 | % |  | 1.6 | %
Amortization as a % of sales | 14.1 | % |  | 14.0 | % |  | 14.4 | % |  | 14.5 | %

Components of Sales Growth

| % Change Three Months Ended June 27, 2025 vs. Comparable 2024 period |  | % Change Six Months Ended June 27, 2025 vs. Comparable 2024 Period
Total revenue growth (GAAP) | (1.3) | % |  | (0.3) | %
Excluding impact of: |  |  |
Currency exchange rates | (0.6) | % |  | 0.5 | %
Core revenue growth (Non-GAAP) | (1.9) | % |  | 0.2 | %

The sales results for the second quarter and year-to-date period were driven by favorable pricing of 2.9% and 2.6%, respectively, and volume increases in software products and dosimetry services. These benefits were offset by a decline in sterilization healthcare equipment and biomedical test tools. Additionally, foreign currency exchange rates impacted sales results as indicated above.
Geographically, in the second quarter, the core revenue decline was driven primarily by weakness in Latin America from sterilization healthcare equipment due to government healthcare budgetary restraints. Western Europe also observed sales declines in certain biomedical test products. In North America, healthcare software experienced increased demand, mitigating the unfavorable impact of softening healthcare equipment sales driven by healthcare policy uncertainty.
Geographically, in the year-to-date period, core revenue was stable, which was driven primarily by growth in North America where increased demand in software products and dosimetry services mitigated the weakness in sterilization healthcare equipment sales. This growth was mostly offset by declines in Latin America, Western Europe and China, from demand weakness in sterilization healthcare equipment and certain biomedical and radiation detection products.
Operating profit margin decreased 20 basis points during the second quarter, as compared to the comparable period of 2024. Year-over-year changes in operating profit margin were comprised of the following:
•Year-over-year increases due to favorable pricing, gains from productivity measures through our FBS initiatives, offset by a net volume decline in the segment, higher employee compensation, and investments in growth initiatives — unfavorable 10 basis points
•The year-over-year effect of amortization from existing businesses — unfavorable 10 basis points
34

Table of Contents
Operating profit margin decreased 40 basis points during the year-to-date period as compared to the comparable period of 2024. Year-over-year changes in operating profit margin were comprised of the following:
•Year-over-year increase due to favorable pricing and gains from productivity measures, offset by a net volume decline, higher employee compensation, and higher costs to support product innovation — unfavorable 50 basis points
•The year-over-year effect of amortization from existing businesses — favorable 10 basis points
COST OF SALES AND GROSS PROFIT

| Three Months Ended |  | Six Months Ended
($ in millions) | June 27, 2025 |  | June 28, 2024 |  | June 27, 2025 |  | June 28, 2024
Sales | $ | 1,518.8 |  |  | $ | 1,552.4 |  |  | $ | 2,993.0 |  |  | $ | 3,076.9 |
Cost of sales | (623.1) |  |  | (624.1) |  |  | (1,216.4) |  |  | (1,244.4) |
Gross profit | $ | 895.7 |  |  | $ | 928.3 |  |  | $ | 1,776.6 |  |  | $ | 1,832.5 |
Gross profit margin | 59.0 | % |  | 59.8 | % |  | 59.4 | % |  | 59.6 | %

The year-over-year decrease in gross profit during both the second quarter and year-to-date period was due to an overall volume decline, higher employee compensation, discrete restructuring charges, and the unfavorable impact from tariffs net of countermeasures. These impacts were partially offset by favorable pricing, gains from productivity measures and FBS initiatives. Additionally, the effect of foreign currency exchanges rates was favorable in the second quarter but unfavorable in the year-to-date period.
OPERATING EXPENSES

| Three Months Ended |  | Six Months Ended
($ in millions) | June 27, 2025 |  | June 28, 2024 |  | June 27, 2025 |  | June 28, 2024
Sales | $ | 1,518.8 |  | $ | 1,552.4 |  | $ | 2,993.0 |  | $ | 3,076.9
Selling, general and administrative (“SG&A”) | 564.3 |  | 525.4 |  | 1,106.5 |  | 1,086.4
Research and development (“R&D”) | 109.2 |  | 101.1 |  | 214.3 |  | 205.2
SG&A as a % of sales | 37.2 | % |  | 33.8 | % |  | 37.0 | % |  | 35.3 | %
R&D as a % of sales | 7.2 | % |  | 6.5 | % |  | 7.2 | % |  | 6.7 | %

The year-over-year increase in SG&A during both the second quarter and year-to-date period were primarily due to costs incurred in 2025 related to the Separation, higher employee compensation, investment for growth initiatives, and discrete restructuring charges, all partially offset by benefits from productivity measures through our FBS initiatives. Additionally, in the year-to-date period, there were lower costs incurred related to acquisitions when compared to last year.
R&D, consisting principally of internal and contract engineering personnel costs, increased during the second quarter and the year-to-date period as compared to the comparable periods of 2024 due to ongoing investments in innovation and higher compensation.
NON-OPERATING INCOME (EXPENSE), NET
Interest costs
Net interest expense for the second quarter and year-to-date period was $32.1 million and $64.1 million as compared to $38.7 million and $82.7 million in the comparable periods in 2024. The year-over-year decrease in net interest expense was primarily due to overall debt mix consisting of lower fixed rate debt instruments, and lower interest rate on floating rate debt instruments. For discussion of our outstanding indebtedness, refer to Note 5 to the consolidated condensed financial statements.
Loss from divestiture
During the three and six-month periods ended June 28, 2024, we recognized a net realized loss of $25.6 million related to the Invetech Divestiture. For further discussion of this transaction, refer to Note 1 to the consolidated condensed financial statements.
35

Table of Contents
Other non-operating income (expense), net
Other non-operating income for the second quarter and year-to-date period was $1.9 million and $1.7 million, as compared to expense of $8.8 million and $33.0 million in the comparable periods in 2024. The year-over-year change in both the second quarter and year-to-date was primarily due to losses from our equity investments recognized in the comparable prior year periods. Additionally there was a charitable contribution made in the first quarter of 2024. For further discussion of the charitable contribution, refer to Note 1 to the consolidated condensed financial statements.
INCOME TAXES
Our effective tax rate for the three and six-month period ended June 27, 2025 was 13.2% and 14.0%, respectively, as compared to 14.7% and 13.0%, respectively, for the three and six-month period ended June 28, 2024. The decrease in the effective tax rate for the three-month period ended June 27, 2025 as compared to the three-month period ended June 28, 2024 was primarily related to a change in mix of earnings in the comparable prior year period. The increase in the effective tax rate for the six-month period ended June 27, 2025 as compared to the six-month period ended June 28, 2024 was primarily related to a discrete tax credit in the comparable prior year period from cash repatriation.
Our effective tax rate for the three and six-month period ended June 27, 2025 , differs from the U.S. federal statutory rate of 21% due primarily to the impact of credits and deductions provided by law, including those associated with state income taxes, and changes in our uncertain tax position reserves.
Globally, the Company monitors legislative action and OECD initiatives related to global taxation. The impact of the OECD framework for a “Pillar Two” global minimum corporate income tax rate of fifteen percent (15%) has been included within the provision for income taxes. On June 28, 2025, the OECD released a statement recognizing an agreement between OECD and the G20 to recognize the U.S. minimum tax rules to exempt U.S. multinationals certain portions of the Pillar Two framework. We continue to monitor further guidance and legislative developments related to the Pillar Two framework.
The One Big Beautiful Bill Act (“OBBBA”) enacted in the U.S on July 4, 2025 resulted in significant income tax provisions with effective dates spanning from 2025 through 2027. Changes from OBBBA include modifications to allow for immediate expensing of certain business investments and provides certain permanent extensions and modifications to the U.S. international tax framework. We are currently assessing the impact of OBBBA on our consolidated financial statements.
COMPREHENSIVE INCOME
Comprehensive income increased by $101 million during the second quarter as compared to the comparable period in 2024 due to favorable changes in foreign currency translation of $129 million, partially offset by a $29 million decrease in net income.
Comprehensive income increased by $212 million during the year-to-date period as compared to the comparable period in 2024 due primarily to favorable changes in foreign currency translation adjustments of $276 million, partially offset by a $64 million decrease in net income.
LIQUIDITY AND CAPITAL RESOURCES
We assess our liquidity in terms of our ability to generate cash to fund our operating, investing, and financing activities. We generate substantial cash from operating activities and believe that our operating cash flow and other sources of liquidity, which consist of available cash, our revolving credit facility, and access to commercial paper, bank loans, and capital markets, will be sufficient to allow us to continue funding and investing in our existing businesses, consummate strategic acquisitions, execute strategic separations, repurchase common stock on the open market or in privately negotiated transactions, make interest and principal payments on our outstanding indebtedness, fulfill our contractual obligations, and manage our capital structure on a short and long-term basis.
We have generally satisfied any short-term liquidity needs that are not met through operating cash flows and available cash through issuances of commercial paper under our U.S. dollar and Euro-denominated commercial paper programs (“Commercial Paper Programs”).
Credit support for the Commercial Paper Programs is provided by a five-year $2.0 billion senior unsecured revolving credit facility that expires on October 18, 2027 (the “Revolving Credit Facility”) which, to the extent not otherwise providing credit
36

Table of Contents
support for the commercial paper programs, can also be used for working capital and other general corporate purposes. As of June 27, 2025, no borrowings were outstanding under the Revolving Credit Facility.
The availability of the Revolving Credit Facility as a standby liquidity facility to repay maturing commercial paper is an important factor in maintaining the existing credit ratings of the Commercial Paper Programs when we have outstanding borrowings. We expect to limit any future borrowings under the Revolving Credit Facility to amounts that would leave sufficient credit available under the facility to allow us to borrow, if needed, and repay any outstanding commercial paper as it matures.
On June 7, 2023, we filed with the SEC an “automatic shelf” registration statement (the “Shelf Registration Statement”). Under the Shelf Registration Statement, we may from time to time sell shares of common stock, preferred stock, debt securities, depository shares, purchase contracts, purchase units, warrants and subscription rights in one or more offerings.
We continue to monitor the financial markets, the stability of U.S. and international banks and general global economic conditions. In addition, our access to the capital markets and other financing sources is impacted by any change in our credit rating. If changes in financial markets or other areas of the economy or downgrade in our credit rating adversely affect our access to the capital markets and other financing sources, we would expect to rely on a combination of available cash and existing available capacity under our credit facilities to provide short-term funding.
Refer to Note 5 of the consolidated condensed financial statements for additional information regarding our financing activities and indebtedness.
Overview of Cash Flows and Liquidity
Following is an overview of our cash flows and liquidity ($ in millions):

| Six Months Ended
| June 27, 2025 |  | June 28, 2024
Net cash provided by operating activities | $ | 552.9 |  |  | $ | 565.6 |
Purchases of property, plant and equipment | $ | (63.4) |  |  | $ | (55.6) |
Proceeds from sale of property | 1.7 |  |  | 10.8 |
Cash paid for acquisitions, net of cash received | — |  |  | (1,721.8) |
Cash infusion into divestiture | — |  |  | (14.0) |
All other investing activities | 10.9 |  |  | (1.6) |
Net cash used in investing activities | $ | (50.8) |  |  | $ | (1,782.2) |
Net proceeds from (repayments of) commercial paper borrowings | $ | (253.2) |  |  | $ | (571.5) |
Repurchase of common shares | (344.5) |  |  | (152.9) |
Payment of dividends | (54.2) |  |  | (56.1) |
Proceeds from borrowings (maturities greater than 90 days), net of issuance costs | 1,146.8 |  |  | 1,733.5 |
Repayment of borrowings (maturities greater than 90 days) | — |  |  | (1,000.0) |
All other financing activities | 14.4 |  |  | 31.9 |
Net cash provided by (used in) financing activities | $ | 509.3 |  |  | $ | (15.1) |

Operating Activities
Cash flows from operating activities can fluctuate significantly from period-to-period as working capital needs and the timing of payments for income taxes, interest, pension funding, and other items impact reported cash flows.
Operating cash flows were $553 million during the year-to-date period, representing a decrease of $13 million when compared to the comparable period of 2024. The year-over-year change in operating cash flows was primarily attributable to the following factors:
•Year-over-year decrease of $25 million in Operating cash flows from net earnings, net of non-cash items (Amortization, Depreciation, Stock-based compensation, Gain on sale of property, and Loss from divestiture).
37

Table of Contents
•The aggregate changes in accounts receivable, inventories, and trade accounts payable generated $32 million of cash during the year-to-date period as compared to generating $43 million in the comparable period of 2024. The amount of cash flow generated from or used by the aggregate of trade accounts receivable, inventories, and trade accounts payable depends upon how effectively we manage the cash conversion cycle, which generally represents the number of days that elapse from the day we pay for the purchase of raw materials and components to the collection of cash from our customers, and can be significantly impacted by the timing of collections and payments in a period.
•The aggregate changes in prepaid expenses and other assets, and accrued expenses and other liabilities used $145 million of cash in the year-to-date period as compared to using $169 million of cash in the comparable period of 2024. The year-over-year changes were driven by timing differences related to payments of employee compensation, income taxes, interest.
Investing Activities
Cash outflows from investing activities declined $1.73 billion when compared with the prior year, which had outflows related to the EA acquisition, net of cash acquired, and cash infusion into divestiture.
Capital expenditures are made primarily for increasing production capacity, replacing aged equipment, supporting product development initiatives for hardware and software offerings, improving information technology systems, and purchasing equipment that is used in revenue arrangements with customers.
Financing Activities and Indebtedness
Cash flows from financing activities consist primarily of cash flows associated with the issuance and repayment of debt and commercial paper, payments of cash dividends to shareholders and share repurchases.
In the year-to-date period, financing activities generated cash of $509 million, reflecting the following transactions:
•We repaid $253 million in net commercial paper borrowings.
•We repurchased 4.4 million shares of our common stock for approximately $345 million, under our share repurchase program.
•We made dividend payments to common shareholders totaling $54 million.
•On June 27, 2025, in preparation for the Separation, Ralliant, a wholly-owned, consolidated subsidiary prior to the Separation, borrowed $1.15 billion in aggregate principal amount of USD Term Loans due 2026 and 2028 (the “Ralliant Debt”).
In the comparable 2024 period, financing activities used cash of $15 million, reflecting the following transaction:
•We repaid $572 million in net commercial paper borrowings.
•On January 2, 2024, we drew down an additional $450 million of the Delayed-Draw Term Loan due 2024 as part of the funding for the acquisition of EA.
•On February 13, 2024, we completed the sale of our registered offering of the 2026 Notes and the 2029 Notes, yielding net proceeds of approximately $1.3 billion.
•On February 13 2024, Fortive repaid $1.0 billion in outstanding principal of the Delayed-Draw Term Loan due 2024, using net proceeds from the 2026 Notes and 2029 Notes.
•We repurchased 2 million shares of our common stock for approximately $153 million under our share repurchase program.
•We made dividend payments to common shareholders totaling $56 million.
Cash and Cash Requirements
As of June 27, 2025, we held approximately $1,833 million of cash and equivalents, including the proceeds from the Ralliant Dividend, that were invested in highly liquid investment-grade instruments with a maturity of 90 days or less, of which approximately 32% was held outside of the United States.
We have cash requirements to support working capital needs, capital expenditures and acquisitions, pay interest and service debt, pay taxes and any related interest or penalties, fund our pension plans as required, pay dividends to shareholders, and support other business needs or objectives. With respect to our cash requirements, we generally intend to use available cash and internally generated funds to meet these cash requirements, but in the event that additional liquidity is required, particularly in connection with acquisitions and repayment of maturing debt, we may also borrow under our commercial paper programs or credit facilities or enter into new credit facilities and either borrow directly thereunder or use such credit facilities to backstop
38

Table of Contents
additional borrowing capacity under our commercial paper programs. We also may from time to time access the capital markets, including to take advantage of favorable interest rate environments or other market conditions.
Foreign cumulative earnings remain subject to foreign remittance taxes. We have made an election regarding the amount of earnings that we do not intend to repatriate due to local working capital needs, local law restrictions, high foreign remittance costs, previous investments in physical assets and acquisitions, or future growth needs. For most of our foreign operations, we make an assertion regarding the amount of earnings in excess of intended repatriation that are expected to be held for indefinite reinvestment. No provisions for foreign remittance taxes have been made with respect to earnings that are planned to be reinvested indefinitely. The amount of foreign remittance taxes that may be applicable to such earnings is not readily determinable given local law restrictions that may apply to a portion of such earnings, unknown changes in foreign tax law that may occur during the applicable restriction periods caused by applicable local corporate law for cash repatriation, and the various tax planning alternatives we could employ if we repatriated these earnings.
As of June 27, 2025, we expect to have sufficient liquidity to satisfy our cash needs for the foreseeable future.
CRITICAL ACCOUNTING ESTIMATES
There were no material changes during the three and six-month periods ended June 27, 2025 to the items we disclosed as our critical accounting estimates in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2024 Annual Report on Form 10-K.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Our concentrations of credit risk arising from trade receivables is limited due to the diversity of our customers. Our businesses perform credit evaluations of their customers’ financial conditions as appropriate and also obtain collateral or other security when appropriate.
Additional quantitative and qualitative disclosures about market risk appear in “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Financial Instruments and Risk Management,” in our 2024 Annual Report on Form 10-K. There were no material changes during the three and six-month period ended June 27, 2025 to the information reported in our 2024 Annual Report on Form 10-K relating to our evaluation of interest rate, foreign currency exchange, and commodity price risk. Refer to Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations for discussion around the impact of these items in the second quarter and year-to-date period.
ITEM 4. CONTROLS AND PROCEDURES
Our management, with the participation of the President and Chief Executive Officer, and the Senior Vice President and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this report. Based on such evaluation, the President and Chief Executive Officer, and the Senior Vice President and Chief Financial Officer, have concluded that, as of the end of such period, these disclosure controls and procedures were effective.
There have been no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the most recent completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II - OTHER INFORMATION
ITEM 1A. RISK FACTORS
Information regarding risk factors appears in “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Information Relating to Forward-Looking Statements,” in Part I - Item 2 of this Form 10-Q and in the “Risk Factors” section of our 2024 Annual Report on Form 10-K. Other than as provided below, there were no material changes during the quarter ended June 27, 2025 to the risk factors reported in the “Risk Factors” section of our 2024 Annual Report on Form 10-K and Part II, Item 1A of our Quarterly Report on Form 10-Q for the quarter ended March 28, 2025.
Potential indemnification liabilities to Ralliant Corporation ("Ralliant") pursuant to the separation agreement could materially and adversely affect our businesses, financial condition, results of operations, and cash flows.
39

Table of Contents
We entered into a separation and distribution agreement and related agreements with Ralliant to govern the separation and distribution of Ralliant and the relationship between the two companies going forward. These agreements provide for specific indemnity and liability obligations of each party and could lead to disputes between us. If we are required to indemnify Ralliant under the circumstances set forth in these agreements, we may be subject to substantial liabilities. In addition, with respect to the liabilities for which Ralliant has agreed to indemnify us under these agreements, there can be no assurance that the indemnity rights we have against Ralliant will be sufficient to protect us against the full amount of the liabilities, or that Ralliant will be able to fully satisfy its indemnification obligations. Each of these risks could negatively affect our businesses, financial condition, results of operations, and cash flows.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
On February 17, 2022, the Company’s Board of Directors approved a share repurchase program authorizing the Company to repurchase up to 20 million shares of the Company’s outstanding common stock from time to time on the open market or in privately negotiated transactions. On January 23, 2024 and May 27, 2025, the Company’s Board of Directors increased the number of shares authorized under the share repurchase program by an additional 11 million and 15.6 million shares, respectively. As of June 27, 2025, there were 19.2 million shares remaining authorized under the share repurchase program. There is no expiration date for the repurchase program, and the timing and amount of repurchases under the program are determined by the Company’s management based on market conditions and other factors. The repurchase program may be suspended or discontinued at any time by the Board of Directors. During the fiscal quarter ended June 27, 2025, the Company purchased 1.9 million shares of its common stock at an average share price of $71.15.
The following table provides details about our share repurchases, including pursuant to a 10b5-01 plan, during the fiscal quarter ended June 27, 2025.

Period | Total number of shares (or units) purchased |  | Average price paid per share (or unit) |  | Total number of shares (or units) purchased as part of publicly announced plans or programs |  | Maximum number (or approximate dollar value) of shares (or units) that may yet be purchased under the plans or programs
March 29 - April 28 | — |  |  | $ | — |  |  | N/A |  | N/A
April 29 - May 28 | 1,271,283 |  |  | 71.03 |  |  | 1,271,283 |  |  | 19,846,970 |
May 29 - June 27 | 626,039 |  |  | 71.40 |  |  | 626,039 |  |  | 19,220,931 |
Total | 1,897,322 |  |  | $ | 71.15 |  |  | 1,897,322 |  |  | 19,220,931 |

Special Purpose Share Repurchase Program
On May 27, 2025, in connection with the Separation, the Company’s Board of Directors adopted a separate special purpose share repurchase program (the “Special Purpose Share Repurchase Program”) under which Fortive may purchase up to $550 million in Fortive’s common stock exclusively from the proceeds of the Ralliant Dividend, together with any other cash received by Fortive from Ralliant in connection with the Separation (collectively, the “Ralliant Cash Proceeds”). Repurchases of shares of Fortive common stock using the Ralliant Cash Proceeds will only be made through the Special Purpose Share Repurchase Program.
ITEM 5. OTHER INFORMATION
Trading Plans
During the second quarter ended June 27, 2025, no directors or Section 16 officers adopted, modified, or terminated any “Rule 10b5-1 trading arrangement” or any “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
ITEM 6. EXHIBITS

Exhibit Number |  | Description
2.1 |  | Separation and Distribution Agreement, dated June 27, 2025, by and between Ralliant Corporation and Fortive Corporation (Incorporated by reference from Exhibit 2.1 to Fortive Corporation’s Current Report on Form 8-K, filed on June 10, 2025. Commission File No. 1-37654).

40

Table of Contents

Exhibit Number |  | Description
3.1 |  | Restated Certificate of Incorporation of Fortive Corporation (I ncorporated by reference from Exhibit 3.1 to F ortive Corporation’s Quarterly R eport on Form 10-Q for the fiscal quarter ended June 28, 2024. Commi ssion File No. 1-37654).
3.2 |  | Amended and Restated Bylaws of Fortive Corporation (I ncorporated by reference from Exhibit 3.1 to Fortive Corporation’s Current Report on Form 8-K, filed on November 8, 2022. Commission File No. 1-37654).
10.1 |  | Fortive Corporation Amended and Restated 2016 Stock Plan (Incorporated by reference from Appendix B to Fortive Corporation’s Proxy Statement on Schedule 14A filed on April 21, 2025. Commission File Number: 1-37654).
10.2 |  | Employee Matters Agreement, dated June 27, 2025, by and between Ralliant Corporation and Fortive Corporation (Incorporated by reference from Exhibit 10.1 to Fortive Corporation’s Current Report on Form 8-K, filed on June 10, 2025. Commission File No. 1-37654).
10.3 |  | Tax Matters Agreement, dated June 27, 2025, by and between Ralliant Corporation and Fortive Corporation (Incorporated by reference from Exhibit 10.2 to Fortive Corporation’s Current Report on Form 8-K, filed on June 10, 2025. Commission File No. 1-37654).
10.4 |  | Transition Services Agreement, dated June 27, 2025, by and between Ralliant Corporation and Fortive Corporation (Incorporated by reference from Exhibit 10.3 to Fortive Corporation’s Current Report on Form 8-K, filed on June 10, 2025. Commission File No. 1-37654).
10.5 |  | Intellectual Property Matters Agreement, dated June 27, 2025, by and between Ralliant Corporation and Fortive Corporation (Incorporated by reference from Exhibit 10.4 to Fortive Corporation’s Current Report on Form 8-K, filed on June 10, 2025. Commission File No. 1-37654).
10.6 |  | FBS License Agreement, dated June 27, 2025, by and between Ralliant Corporation and Fortive Corporation (Incorporated by reference from Exhibit 10.5 to Fortive Corporation’s Current Report on Form 8-K, filed on June 10, 2025. Commission File No. 1-37654).
10.7 |  | Fort Solutions License Agreement, dated June 27, 2025, by and between Ralliant Corporation and Fortive Corporation (Incorporated by reference from Exhibit 10.6 to Fortive Corporation’s Current Report on Form 8-K, filed on June 10, 2025. Commission File No. 1-37654).
10.8 |  | Credit Agreement, dated as of May 15, 2025, among Ralliant Corporation, PNC Bank, National Association, as Administrative Agent, L/C Issuer and Swing Line Lender, and the other Lenders party thereto (Inco rporated by reference from Exhibit 10.1 to Fortive Corporat ion’s Cur rent Report on Form 8-K, filed on May 19, 2025. Commission File No. 1-37654).
31.1 |  | Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. †
31.2 |  | Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. †
32.1 |  | Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. †
32.2 |  | Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. †
101.INS |  | XBRL Instance Document - the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. †
101.SCH |  | Inline XBRL Taxonomy Extension Schema Document †
101.CAL |  | Inline XBRL Taxonomy Extension Calculation Linkbase Document †
101.DEF |  | Inline XBRL Taxonomy Extension Definition Linkbase Document †

41

Table of Contents

Exhibit Number |  | Description
101.LAB |  | Inline XBRL Taxonomy Extension Label Linkbase Document †
101.PRE |  | Inline XBRL Taxonomy Extension Presentation Linkbase Document †
104 |  | The cover page from this Quarterly Report on Form 10-Q for the quarter ended June 27, 2025, formatted in Inline XBRL and contained in Exhibit 101.

* | Indicates management contract or compensatory plan, contract or arrangement.
† | Filed electronically herewith.

42

Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| FORTIVE CORPORATION:
Date: July 30, 2025 | By: | /s/ Mark D. Okerstrom
|  | Mark D. Okerstrom
|  | Senior Vice President and Chief Financial Officer
Date: July 30, 2025 | By: | /s/ Christopher M. Mulhall
|  | Christopher M. Mulhall
|  | Chief Accounting Officer

43